

**EMORY UNIVERSITY SCHOOL OF MEDICINE**  
**STANDARD CURRICULUM VITAE FORMAT**

1. Name: Ighowwerha (Igho) Ofotokun, MD, MSc, FIDSA
2. Office Address: Emory University School of Medicine  
Department of Medicine  
Division of Infectious Diseases  
49 Jesse Hill Jr. Drive  
Atlanta, GA 30303  
Phone 404-616-0659  
Fax 404-616-0592
3. E-mail Address: [iofotok@emory.edu](mailto:iofotok@emory.edu)
4. Citizenship: United States Citizen
5. Current Titles and Affiliations:
  - a. Academic Appointments:
    - i. Primary Appointments:
      1. Grady Distinguished Professor of Medicine, Division of Infectious Diseases, Department of Medicine, School of Medicine: 2022 - Present
      2. Professor of Medicine, Division of Infectious Diseases, Department of Medicine, School of Medicine: 2016 - Present
    - ii. Joint Appointment:
      1. Professor of Behavioral Science and Health Education, Rollins School of Public Health, Emory University: 2016 - Present
  - b. Clinical Responsibilities:
    1. Staff Physician, Grady Memorial Health System Infectious Disease Program: 2003 – Present
  - c. Other Administrative Responsibilities:
    1. Director, Atlanta MACS/WIHS Combined Cohort Study: 2013 – Present
    2. Co-Director, Emory Building Interdisciplinary Research Careers in Women's Health (BIRCWH): 2015 – Present
    3. Co-Program Director, Georgia Clinical and Translational Science Alliance KL2 Program: 2015– Present
    4. Co-Director, Emory Center for AIDS Research (CFAR), Clinical Core: 2016 – Present
    5. Co-Director, Emory Stimulating Access to Research for Residence Physician (StARR) R38: 2018 – Present
    6. Co-Chair, Mentorship, Training and Education Committee, Infectious Diseases Clinical Research Consortium (IDCRC) Leadership Group for the Vaccine Treatment and Evaluation Units (VTEU): 2020 - Present
    7. Associate Director for Research, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine: 2020 – Present
    8. Co-Director, Atlanta Researching COVID to Enhance Recovery (RECOVER): 2021- Present
    9. Associate Dean of Research Development, Emory University School of Medicine: 2023 - Present

6. Previous Academic and Professional Appointments:
  - a. Chief Medical Officer, Eku Baptist Hospital Nigeria: 1990 – 1994
  - b. Instructor, School of Medicine, University of Michigan: 1998 – 1999
  - c. Assistant Professor of Medicine, University of Kentucky: 2001 – 2003
  - d. Assistant Professor of Medicine, Emory University School of Medicine: 2003 – 2010
  - e. Associate Professor of Medicine, Division of Infectious Diseases, School of Medicine: 2010 – 2016
  - f. Professor of Medicine, Division of Infectious Diseases, School of Medicine: 2016 – Present
  - g. Tenured Professor of Medicine, Division of Infectious Diseases, School of Medicine: 2020
  - h. Grady Distinguished Professor of Medicine, Division of Infectious Diseases, School of Medicine: 2022
7. Previous Administrative and/or Clinical Appointments:
  - a. Chief Medical Officer, Eku Baptist Hospital, Nigeria: 1993-1994
  - b. Staff Physician, Ann Arbor Veteran Affairs Medical Center: 1998 – 1999
  - c. Staff Physician University of Kentucky Medical Center: 2001 – 2003
  - d. Director, Antimicrobial Stewardship, University of Kentucky Hospital: 2001 – 2003
8. Licensures/Boards:
  - a. Michigan Board of Medical Licensure (inactive)      Issued: 1995
  - b. Kentucky Board of Medical Licensure (inactive)      Issued: 2001
  - c. Georgia Board of Medical Licensure (active)      Issued: 2003
9. Specialty Boards:
  - a. American Board of Internal Medicine Board: 1999, 2009, 2019
  - b. American Board of Internal Medicine Board (Infectious Diseases): 2002, 2012, 2022
10. Education
  - a. B.Sc. Pharmacology, University of Ibadan, Nigeria: 1980 – 1983
  - b. MB:BS: University of Benin, Nigeria: 1985 – 1990
  - c. MSc: Emory University, Atlanta, GA: 2003 – 2005
11. Postgraduate Training:
  - a. Internship in Internal Medicine, University of Michigan, Ann Arbor, Dr. JC Kolars: 1995 – 1996
  - b. Residency in Internal Medicine, University of Michigan, Ann Arbor, Dr. P. Kazanjian: 1996 – 1998
  - c. Fellowship, Infectious Diseases, University of Michigan, Ann Arbor, Dr. D. Markovitz: 1999 – 2001
12. Continuing Professional Development Activities:
  - a. Emory Medicine Professional Leadership Enrichment and Development Program, EM ProLEAD: 2015
13. Military or Government Service:
  - a. Nigerian National Youth Service Corp: 1984-1985
14. Committee Memberships:
  - a. National and International:
    - I. NIH-Funded AIDS Clinical Trials Group (ACTG)

1. ACTG Pharmacology Committee, Member: 2002 – 2007
  2. ACTG Underrepresented Populations Working Group, Member: 2004 – 2007
  3. ACTG Women's Health Committee, Member: 2005 – 2007
  4. National Institute of Allergy and Infectious Diseases (NIAID)/ACTG Combination Task Force on Novel Antiretroviral Combinations for Treatment-naïve HIV-infected Subjects, Member: 2007 – 2011
  5. ACTG Translational Research and Drug Development Committee, Member: 2007 – 2009
  6. Study Monitoring Committee (Data Safety Monitoring Board – DSMB) for the ACTG, Member: 2007 – 2009
  7. ACTG 5257 Study: A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-naïve HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir, with Emtricitabine/Tenofovir for Naïve Treatment), Protocol Vice-Chair: 2008 – Present
  8. Study Monitoring Committee (DSMB) for ACTG, Co-Chair: 2009 – 2012
  9. ACTG 5299 Study, A Randomized, Placebo Controlled Phase 1 Study to Assess the Safety, Pharmacokinetics, and Antiviral Efficacy of Subcutaneous Ibalizumab, an Anti-CD4 Monoclonal Antibody in HIV-1 Infected Patients, Protocol Chair: 2010 – 2014
  10. ACTG 5303 Study: A Phase 2b Double-Blind Placebo-Matched Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-containing Antiretroviral Regimen in Treatment-naïve Patients Infected with R5-Tropic HIV-1, Protocol Member: 2010 – Present
  11. ACTG Bone Working Group, Member: 2012 – Present
  12. ACTG Antiretroviral Therapy Strategies Subcommittee, Member: 2014 – 2016
  13. ACTG-ARTSC broadly neutralizing monoclonal antibodies (bNAbs) Working Group: 2017 – 2018
  14. ACTG Antiretroviral Therapy Strategies Subcommittee, Vice Chair: 2016 – 2017
  15. ACTG Antiretroviral Therapy Strategies Transformative Science Group (TSG), Ex-officio Chair: 2017 – 2018
  16. ACTG Antiretroviral Therapy Strategies TSG Study Monitor Group, Chair: 2018 – 2021
- II. NIH-Funded Women Interagency HIV Study (WIHS)
1. WIHS National Executive Committee, Member: 2012 – 2019
  2. WIHS Pharmacology Working Group, Member: 2012 – 2019
  3. WIHS Metabolic/Cardiovascular Working Group, Member: 2012 – 2019
  4. WIHS Female Genital Tract/Pathogenesis Working Group, Co-Chair: 2014 – 2016
  5. WIHS Female Genital Tract/Pathogenesis Working Group, Member: 2016 – 2019
- III. NIH-Funded Multicenter AIDS Cohort Study/Women Interagency HIV Study Combine Cohort Study (MWCCS)
1. MWCCS Executive Committee, Member: 2017 – Present
  2. MWCCS Investigator Developmental Award Advisory Committee (IDAC), Member: 2018 – Present
  3. MWCCS Protocol Development Committee, Member: 2019 – 2020

4. MWCCS Pharmacology Working Group, Member: 2019 – Present
  5. MWCCS Metabolic Working Group, Member: 2019 – Present
  6. MWCCS Viral Immune Pathogenesis Working Group, Member: 2019 – Present
  7. MWCCS Investigator Development Award Advisory Committee (IDAC), Member: 2019 - Present
- IV. Infectious Diseases Society of America (IDSA)/HIV Medicine Association (HIVMA):
1. IDSA Research Committee, Member: 2013 – 2016
  2. HIVMA Research Award Committee, Member: 2013 – 2016
  3. HIVMA Board, Member: 2017 – 2019
  4. IDSA Governing Board, HIVMA Representative: 2017 – 2019
  5. IDSA Publication Committee, IDSA Board Liaison: 2017 – 2019
  6. HIVMA Leadership Development Committee, Chair: 2018 – 2021
  7. IDSA Leadership Development Committee, Member: 2018 – 2021
  8. Clinical Infectious Diseases Journal Editor-in-Chief Search Committee, Member: 2021
  9. IDSA Awards Committee, Member: 2021 - Present
  10. IDSA Leadership Institute Working Group, Member: 2021 – Present
- V. Other National/International Services:
1. Nigerian Medical School Curriculum Review Committee – Reviewed and revised the national curriculum for medical education, Section Chair: 2011 – 2013
  2. Association of Nigerian Physicians in the Americas, Infectious Diseases Committee, Member: 2015 – Present
  3. Nigeria Institute of Medical Research (NIMR) Research Advisory Board, Member: 2017 – Present
  4. Nigeria Governors Forum COVID-19 Advisory Group (NGF-CAG), Member: 2020 - Present
- b. Regional:
1. Kentucky HIV/AIDS Advocacy & Action Group, Member: 2001 – 2003
  2. Executive Committee of Research Education, Training and Career Development (RETCD), Georgia Clinical and Translational Science Institute (ACTSI), Member: 2009 – Present
- c. Institutional:
1. Antimicrobial Subcommittee, University of Kentucky Hospital, Chair: 2001 – 2003
  2. Pharmacy & Therapeutic Committee, University of Kentucky Hospital, Member: 2001 – 2003
  3. Policy and Operations Team, University of Kentucky Hospital Pharmacy, Member: 2002 – 2003
  4. Infection Control Committee, University of Kentucky Hospital, Member: 2002 – 2003
  5. Emory Infectious Diseases Division Education Committee, Member: 2005 – 2012
  6. Emory University Department of Medicine Early Career Committee, Member: 2006 – 2010
  7. Emory Center for AIDS Research Internal Scientific Advisory Committee, Member: 2006 – Present
  8. Grady Health System Pharmacy and Therapeutic Committee, Member: 2007 – Present
  9. Emory University Clinical Investigator’s Advisory Council, Member: 2008 – 2020

10. Executive Committee for Emory University Medical Student Research, Member: 2009 – 2013
11. Department of Medicine Promotion and Tenure Committee, Member: 2011 – 2014
12. Emory Medical Care Foundation Research Committee, Member: 2012 – Present
13. Department of Medicine Career Development Awards (CDA) Committees: 2013 – Present
14. School of Medicine Faculty Committee for Appointment and Promotion, Member: 2014 – 2017
15. Grady Infectious Diseases Program (Grady IDP) Research Steering Committee, Chair: 2015 – Present
16. Executive Committee for the Division of Infectious Diseases, Emory University School of Medicine, Member: 2015 – Present
17. Emory Center of AIDS Research Council, Member: 2015 - Present
18. Woodruff Health Sciences (WHSC) Innovative Discovery Subject Matter Expert (SME) Team for the WHSC Strategic Plan, Member: 2017
19. Emory University Grady Campus Space Committee, Member: 2020 – Present
20. Emory Department of Medicine Standing Faculty Search Committee, Member: 2021 – Present
21. Search Committee, Dean, Emory University Rollins School of Public Health: 2021

15. Peer Review Activities:

a. Grants:

I. National and International:

1. Ad hoc Reviewer, NIH (NIAID) Center for AIDS Research Supplemental Grant: 2003
2. Ad hoc Reviewer, Michael Smith Foundation for Health Research: Grant, British Columbia, Canada: 2003 – 2005
3. Ad hoc Reviewer, AIDS Clinical Trials Group: 2005 – Present
4. Ad hoc Reviewer, NIH Study Section, AIDS Clinical Studies and Epidemiology (ACE): 2011 – 2014
5. NIH Study Section, Charter Member of the AIDS Clinical Studies and Epidemiology (ACE) Study Section: 2013 – 2018
6. NIH Special Emphasis Panels (ZRG1 BDA-Q 02 R:PAR10 066 international collaborative project career development, 05 ZAI1 EWS-A (M1) 1P01, and NIAID Clinical Trial Planning Grants review panel: 2012 – Present
7. HIV Comorbidities and Clinical Studies (HCCS) Study Section, 2018 – 2019
8. Chair and Review Panel Member, NIH Special Emphasis Panel, 2019

II. Regional:

1. Atlanta Clinical and Translational Science Institute KL2-Mentored Clinical and Translational Research Scholar (MCTRS) Program: 2009 – Present
2. Atlanta Clinical and Translational Science Institute MSCR (TL1) Program: 2009 – Present
3. Study Protocol Reviewer, Atlanta Clinical and Translational Science Institute (ACTSI) Clinical Interaction Network: 2009 – Present
4. Study Protocol Reviewer, Atlanta Clinical and Translational Science Institute Scientific Advisory Committee: 2009 – 2015

5. Co-Chair, Atlanta Clinical and Translational Science Institute Scientific Advisory Committee: 2015 – Present
6. Chair, Clinical Interaction Network Scientific Advisory Committee for the Georgia Clinical and Translational Alliance: 2017 – 2021
7. Co-Director, Georgia CTSA (Emory University, Georgia Institute of Technology, Morehouse School of Medicine and the University of Georgia, Athens) K-Advance Program: 2015 – Present

III. Institutional:

1. Reviewer, Emory Center for AIDS Research – R03 grants: 2008 – Present
2. Reviewer, Emory Medical Care Foundation Grant: 2012 – 2016
3. Ad hoc Reviewer, University Research Committee: 2014

b. Manuscripts:

1. Antiviral Therapy: 2003 – Present
2. Clinical Infectious Diseases: 2003 – Present
3. Clinical Therapeutics: 2006 – Present
4. Expert Opinion on Pharmacotherapy: 2007
5. Future Medicine: 2008
6. HIV Clinical Trials: 2008 – Present
7. Journal of AIDS Research and Human Retroviruses: 2008 – Present
8. Journal of Clinical Nephrology: 2008
9. Journal of Clinical Microbiology: 2008
10. The Lancet: 2013 – Present
11. Open Forum Infectious Diseases: 2014
12. African Journal of Laboratory Medicine: 2014 – Present
13. Journal of Acquired Immunodeficiency: 2014 – Present
14. American Journal of the Medical Sciences: 2015 – Present
15. Nature Communications: 2020 – Present

c. Conference Abstracts:

I. National and International:

1. International Conference of African Society of Laboratory Medicine: 2014 – 2019
2. Nigeria Institute of Medical Research Annual Scientific Conference: 2014 - Present
3. Infectious Diseases Society of America Annual Conference: 2015
4. Clinical and Translational Science Association Annual Conference, Abstract Judge: 2015

II. Institutional:

1. Emory Medical Student Research Day, Abstract Judge: 2012 – Present
2. Department of Medicine Research Day, Abstract Judge: 2013 – Present
3. Emory Health Services Research Day, Abstract Judge: 2017 – Present

16. Consultantships/Advisory Boards:
  - a. Otsuka Pharmaceutical Development & Communication, Consultant: 2008 – 2010
  - b. Atlanta Clinical and Translational Science Institute (ACTSI) Scientific Advisory Board, Member: 2008 – Present
  - c. Nigerian Government Experts' Committee on Ebola Virus Disease and other Emerging Infectious Diseases, Resource Consultant: 2014
  - d. Food and Drug Administration (FDA), Special Government Employee/Consultant to FDA Antimicrobial Drugs Advisory Committee: 2015 – 2016
  - e. Accordant Health Services, Advisory Board: 2016 – Present
  - f. FDA Antimicrobial Drugs Advisory Committee, Member: 2016 – Present
  - g. Nigerian Institute of Medical Research Research Advisory Board, Member: 2017 – Present
17. Editorships and Editorial Boards:
  - a. Antiviral Therapy, Editorial Board Member: 2014
  - b. Journal of the African Society of Laboratory Medicine, Editorial Board Member: 2015 – 2019
  - c. AIDS Research and Human Retroviruses, Associate Editor: 2017 – 2019
18. Honors and Awards
  - a. Shanta M. Zimmer Mentorship Award, Emory Division of Infectious Diseases: 2010
  - b. Fellow, Southern Society of Clinical Investigation: 2011
  - c. Fellow, Infectious Diseases Society of America: 2012
  - d. Visiting Professor, Department of Medicine, University of Michigan: 2012
  - e. HIV Medicine Association (HIVMA) National Research Award: 2013
  - f. Shanthi V. Sitaraman Silver Pear Mentorship Award, Emory Department of Medicine: 2014
  - g. Emory Global Health Institute Fellow: 2014
  - h. Visiting Professor, Department of Medicine, University of North Carolina: 2016
  - i. Nanette K. Wenger Distinguished Service Faculty Award, Emory Department of Medicine: 2017
  - j. Paul Beeson's Award (Life Achievement), Emory Infectious Diseases Division: 2018
  - k. R. Wayne Alexander Research Excellence Award, Emory Department of Medicine: 2020
  - l. Visiting Professor, Department of Medicine, Washington University: 2020
  - m. Visiting Professor, Department of Molecular Microbiology and Immunology, Johns Hopkins University: 2021
  - n. Bri Walker Trailblazer Award for the 5<sup>th</sup> Annual Barbara Vick Impact Awards, Emory Center for AIDS Research Community Liaison Council: 2021
  - o. Elected to Emory University Woodruff Leadership Academy: 2022
  - p. Emory University nominee for the National Academic of Medicine: 2022
  - q. School of Medicine Grady Distinguished Professor of Medicine: 2022
19. Society Memberships:
  - a. Infectious Disease Society of America: 2000 – Present
  - b. HIV Medicine Association: 2003 – Present

- c. International AIDS Society (IAS): 2006 – Present
  - d. South Society for Clinical Investigation: 2008 – Present
  - e. American College of Clinical Pharmacology: 2008 – 2010
20. Organization of Conferences:
- a. National and International:
    - I. Administrative Positions:
      - 1. Organizing Committee Member, NIH Sponsored Annual National Pre-doctoral (TL1) and Post-doctoral (TL2) Programs Meeting: 2012 – Present
      - 2. Pre-course Organizer, Annual Scientific Workshop of the Nigerian Institute of Medical Research (NIMR):2012 – Present
      - 3. Organizing Committee Member, Infectious Diseases Society of America (IDSA)/NIH Research Fellows Meeting: 2013 – 2018
      - 4. Vice Chair, IDSA/NIAID Research Fellows Annual Meeting Committee: 2018
    - II. Sessions as Chair:
      - 1. Grant Writing Session Chair, Nigerian Institute of Medical Research Annual Scientific Conference, Lagos, Nigeria:2012
      - 2. Mentoring Session Chair, Infectious Diseases Society of America (IDSA)/NIH Research Fellows Meeting, Bethesda, MD: 2013
      - 3. HIV/AIDS Session Chair, Nigerian Institute of Medical Research 2<sup>nd</sup> International Scientific Conference, Abuja, Nigeria: 2014
      - 4. Co-chair, Microbiome Seminar, NIH/WIHS/MACS Bethesda, MD: 2014
      - 5. Co-chair, HIV Complications and End-organ Damage Session, Infectious Diseases Society of America Annual Conference (IDWEEK): 2015.
      - 6. Organizing Committee Chair, Sex Differences in HIV/AIDS Session, Organization for the Study of Sex Differences (OSSD) Annual Conference: 2020
      - 7. Co-Chair, Steering Committee, NIH Office of Research on Women’s Health Specialized Centers of Research Excellence (SCORE) Annual Meeting, December 145, 2021, Virtual.
      - 8. Co-Chair, HIV Comorbidities Session, American Conference for the Treatment of HIV (ACTHIV): 2022
  - b. Regional:
    - I. Administrative Positions:
      - 1. Organizing Committee Member, 3<sup>rd</sup> Annual Workshop on Antiviral Pharmacometrics, University of Alabama, Birmingham, AL: 2007
      - 2. Session Chair, Southeastern Regional Clinical & Translational Science Conference, March 4 – 5, 2021, Virtual
21. Community Outreach
- a. Leadership Team, Boy Scouts of America, Troop 231: 2012 – 2016
  - b. Children’s Sunday School Teacher, Grace Fellowship Church: 2008 – 2011
  - c. Refugee Outreach Volunteer, Grace Clarkston Clinic: 2016 – Present
22. Formal Teaching:



- a. Medical Student Teaching:
  1. Infectious Diseases Workshop on antibiotics for M-3 (2 hours/year), University of Kentucky: 2001 – 2003
  2. M3 Preceptor (1 hour/week) – University of Kentucky Clerkship Program (MD821): 2001 – 2003
  3. Precepts M3/M4 during their monthly infectious diseases' outpatient clinic rotation through the Grady Infectious Diseases Program (between 4 – 6 students a year in half day/week clinic): 2003 – 2019
  4. M2 Preceptor (1 hour/week) – Emory University Clinical Methods: 2003 – 2004
  5. Infectious Diseases Lecture Series (1 hour/year), Emory University M3: 2003 – 2005
  6. Prologue II (2 hour/year): Emory University M2 annual workshop on antiretroviral drugs and mechanisms of HIV drug resistance: 2007 – Present
  7. Annual Malaria Lecture: A 1 hour/year didactic lecture to M2 student: 2009 – 2015
  8. Critical Review of the Medical Literature (1 hour/year): Annual Medical Students' Discovery Phase Lecture: 2010 – 2013
  9. Review of Medical School Discovery Phase Research Proposals (3 hours/year): 2010 – 2013
  10. Grading of Medical School Discovery Phase Final Research Project Submissions (3 hours/year): 2010 – 2013
- b. Graduate Programs
  - I. Residency Programs:
    1. Infectious Diseases lecture series: Internal Medicine Noon Conference (1 hour/year), University of Kentucky: 2001 – 2003
    2. Precepts medicine house staff during their monthly infectious diseases' outpatient clinic rotation through the Grady Infectious Diseases Program (about 3 residents per year in half day/week clinic): 2003 – Present
    3. Infectious Diseases lecture series (1 hour/year): Medicine Noon Conference, Emory University: 2008
  - II. Fellowship Programs:
    1. Annual case of the week presentation to Infectious Diseases fellows (1 hour/year): 2003 – Present
    2. Didactic lectures to infectious Diseases Fellows (1 hour/year): 2003 – Present
    3. Co-director – infectious diseases monthly journal club (2 hours): 2008 – 2016
  - III. Master's and PhD Programs:
    1. Co-Director: Emory University Master of Science in Clinical Research (MSCR) monthly Journal Club (1.5 hours/year): 2009 – Present
    2. Invited speaker at Emory MSCR Clinical Trial Design, Conduct, and Analysis; BIOS520M on "CONSORT and other publishing guidelines" (1 hour/year): 2010 – 2013
    3. Co-Course Director: MSCR592: Emory University MSCR Clinical Research Colloquium Course (2 hours/week – Spring Semester): 2011 – Present
- c. Other Categories:
  1. Lecturer, Physician Assistance Infectious Diseases Core lecture (1 hour/year): University of Kentucky: 2001 – 2003

2. Co-Director, Emory Ethiopia Fogarty Scholar and MEPI Scholar Programs Journal Club: 2013 – 2017

3. Co-Director, Emory Republic of Georgia Fogarty Scholar Program Journal Club: 2013 – 2017

23. Supervisory Teaching:

a. Postdoctoral Fellows Directly Supervised (served as primary research mentor during infectious diseases fellowship training, Master of Science in clinical research, and/or M4 Discovery Phase):

Table 1. Previous and Current Mentees				
	Name, Year, Position at Start of Mentorship	Project and Mentorship Role	Accomplishments	Mentee's Current Position
<b>Current Mentees</b>				
1	Shellee Grim, PharmD 2001 – 2003 University of Kentucky Pharmacy Residency	Clinical HIV/AIDS and Antiretroviral Therapy <b>(Primary clinical mentor)</b>	2 mentored publications	Clinical Assistant Professor, College of Pharmacy, University of Illinois, Chicago, IL
2	Sarah Smithson, MD, MPH 2005 Emory Medical Student	Liver Enzymes Elevation and Immune Reconstitution among Naïve HIV+ Patients Instituting ART. <b>(Primary research mentor)</b>	1 mentored publication	Assistant Professor of Medicine, UNC, Chapel Hill, NC
3	Kelly White, PharmD 2006 – 2008 Grady Pharmacy Residency	Evaluation of the Efficacy and Safety of Enfuvirtide Therapy in HIV Patients at Grady Health System <b>(Research co-mentor)</b>	1 mentored publication	Senior Clinical Science, Manager, Abbott, Laboratories, Boston, MA
4	Runa Gohkhale, MD 2008 Emory Medicine Residency	TDF Associated ARF and Fanconi Syndrome in ART Naïve HIV Patients: Risk Assessment <b>(Primary research mentor)</b>		Epidemic Intelligence Service (EIS), CDC
5	Julie Gutman, MD, MSc 2008 – 2010 Emory Faculty	Antimalarial PK in <i>P. falciparum</i> infected pregnant women in Brazil <b>(Research co-mentor)</b>	NIH-funded institutional KL2 Award (2008)	Epidemiologist, Malarial Branch, CDC
6	Anandi Sheth, MD, MSc 2008 – 2018 ID Fellow 2011 – 2013 Emory Faculty	Pharmacologic modulation of FGT mucosal immunity <b>(Primary research mentor)</b>	4 mentored publications 2 mentored book chapters IAS Young Investigator Award (2011) NIH-funded Institutional KL2 Award (2012) Emory Medical Care Foundation Award (2012) NIAID K 23 Award (2014-2019) Recipient of R01 equivalent award from the NIH funded Adolescent Trial Network MPI, NICHD R01 (2019-24) Successful R01 (2021-26)	Associate Professor, Division of infectious Diseases, Emory University
7	Lisa Haddad, MD, MPH 2009 – 2018 Family Planning Fellow 2011 – 2012 Emory Faculty	Safe family planning in high-risk population <b>(Primary research mentor)</b>	1 mentored publication 2 mentored book chapters MPH degree NICHD K 23 award (2014-19) Successful NICHD R01 Award (2019)	Director of Research – Private Sector, not-for-profit organization
8	Emily B. Ambinder, MD, MSc 2010 – 2012 MSCR student Medical student	Antiretroviral induced bone loss <b>(Primary research mentor)</b>	1 mentored publication Completed Emory MSCR Recipient of the 2012 CROI Investigator Award Recipient of the 2012 IDSA Medical Scholars Program in the Laboratory Recipient of the 2012 Carolyn L. Kuckein Student Research Fellowship Award	Radiology Residency, Johns Hopkins University
9	Cecile D Lahiri, MD, MSc 2010 – Present	Defining antiretroviral PK/PD in reservoir tissues in women and men <b>(Primary research mentor)</b>	Successful R01 Award (2020) NIH K23 Award (2016-21) Emory KL2 Award EMCF Award NIH supplement 6 mentored peer reviewed publications	Associate Professor, Division of Infectious Diseases, Emory University

<b>Table 1. Previous and Current Mentees</b>				
	<b>Name, Year, Position at Start of Mentorship</b>	<b>Project and Mentorship Role</b>	<b>Accomplishments</b>	<b>Mentee's Current Position</b>
10	Kehmia Titanji, PhD 2012 – Present Emory Faculty	B-cell dysregulation and complications of chronic HIV-infection <b>(Primary research mentor)</b>	6 mentored publications URC Award 2015 NIH K01 Award (2016-21) NHLBI R03 (2020-23)	Assistant Professor, Division of Endocrinology, Emory
11	Sandra Zaeh, MD, MPH 2013 Emory Medical Student Discovery Phase	TB screening in HIV-infected individuals in resource limited settings <b>(Primary research mentor)</b>	1 mentored publication Recipient of the 2012 CROI Investigator Award Recipient of the 2012 IDSA Medical Scholars Program Award Recipient of the 2012 Emory Global Health Institute Individual Field Scholars Award Recipient of the 2012 Benjamin H. Kean Fellowship in Tropical Medicine Award	Internal Medicine Residency, John Hopkins University
12	Russell Kempker, MD, MSc. 2013 – Present Emory Faculty	Anti-TB PK in cavitory lesions <b>(Research co-mentor)</b>	1 mentored publication NIAID K 23 (2013-17) Successful NIAID R21 Award (2017)	Associate Professor, Division of Infectious Diseases, Emory University
13	Katherine Dugan, MA, MD 2014 Emory Medical Student Discovery Phase	Effect of lopinavir on human papillomavirus (HPV) infection and cervical cytology among HIV-infected women <b>(Primary research mentor)</b>	1 mentored peer-reviewed publication 2 mentored poster abstract presentation 1 mentored oral abstract presentation	OB-GYN Residency, Yale University
14	Alfredo Aguirre, BS, MD 2014 Emory Medical Student Discovery Phase	Do plasma or hair antiretroviral drug concentrations predict persistent low-level viremia among HIV-infected women? <b>(Research co-mentor)</b>	1 mentored abstract (submitted)	Internal Medicine Residency, University of California, San Francisco
15	Khadija Jones 2014 – 2015 Emory Undergraduate	Isolation and comparison of cervical vaginal lavage and peripheral blood mononuclear cells in women with HIV to understand the reliability of their use in flow cytometry experiments <b>(Primary research mentor)</b>	1 mentored abstract	Emory University Undergraduate, Biology Major
16	Renee Donahue-Carlson, MD, MSc 2014 – 2017 ID Fellow	Impact of microbiome changes on antiretroviral (atazanavir, darunavir, and raltegravir) exposure in the FGT <b>(Primary research mentor)</b>	Completed the Emory MSCR program (2016) BMS Virology Fellowship Award (2014) 2 mentored abstract presentations (2016 IAS, 2016 IDWEEK) 2 mentored manuscripts under preparation	Private Practice, MN
17	Caitlin Moran, MD, MSc. 2014 – Present Emory Faculty	Predictors of cardiovascular risk in HIV infected women <b>(Primary research mentor)</b>	BMS Virology Fellowship Award (2015) 2 mentored abstract presentation (2017 CROI, 2017 SSCI meeting –oral) Recipient of the CROI Young Investigator Award (2017) Recipient – Emory KL2 Award (2018-2020) Successful NIH K23 (2020)	Assistant Professor, Division of Infectious Diseases, Emory University
18	Marcos Schechter, MD 2014 ID Fellow	Monitoring responses to Isoniazid Preventive Treatment in HIV-infected individuals <b>(Research co-mentor)</b>		Assistant Professor, Division of Infectious Diseases, Emory University
19	Christina Gavegnano, PhD 2015 – 2017	Defining the viral reservoir and factors driving reservoir persistence and reactivation in HIV-infected women <b>(Research co-mentor)</b>	Successful NIH WIHS supplement - \$70, 000	Assistant Professor, Department of Pediatrics, Emory University
20	Smita Iyer, PhD, 2015 – 2017	Single-cell transcriptional profiling of HIV target CCR5+ $\alpha$ 4 $\beta$ 7+ CD4 T cells in the female genital tract <b>(Research co-mentor)</b>	Successful NIH WIHS supplement - \$99, 000	Assistant Professor, UC- Davis
21	Vasiliki Michopoulos, PhD, MSc 2015 - 2018	The effects of HIV on psychophysiological hyperarousal in traumatized women <b>(Research co-mentor)</b>	Successful BIRCHW application – one of 3 inaugural Emory BIRCHW scholars	Assistant Professor, Department of Psychiatry and Behavioral Science, Emory University

<b>Table 1. Previous and Current Mentees</b>				
	<b>Name, Year, Position at Start of Mentorship</b>	<b>Project and Mentorship Role</b>	<b>Accomplishments</b>	<b>Mentee's Current Position</b>
22	Anar Patel, MD 2016 – 2018 ID Fellow	Impact of microbiome changes on antiretroviral (atazanavir, darunavir, and raltegravir) exposure in the FGT <b>(Primary research mentor)</b>	Accepted into the Emory MSCR Program (2016) Recipient, Young Investigator Award, Conference of Retroviruses and Opportunistic Infections (2018)	Private Practice, Cincinnati, Ohio
23	Lauren Collins, MD, 2018 - Present	Non-AIDS co-morbidities in people living with HIV – The impact of HIV serostatus, age, and sex <b>(Primary research mentor)</b>	Completed Emory MSCR program (2020) Awarded Emory KL2 career development grant (2020)	Assistant Professor, Division of Infectious Diseases, Emory
24	Marisa Young, MD, 2020 - Present	Trichomonas vaginalis through the lifespan <b>(Primary research mentor)</b>	Applied for NIAID K23 application (2021)	Assistant Professor, Gyn & OB Department, Emory
25	Jared Eckman, 2020 - Present	Burden of non-communicable diseases among persons living with HIV in low-and-middle Income settings <b>(Primary research mentor)</b>	Applying for Emory MSCR program (2022)	Assistant Professor, Gyn & OB Department, Emory
26	Yetunde Fatade, MD, 2020 - Present	Racial disparity in the vascular complications of COVI-19 <b>(Primary research mentor)</b>	Recipient of Emory StARR R38 award (2020)	Emory Internal Medicine Resident
27	Phoebe Taiwo, 2021 – Present	Scholarly Inquiry and Research Program (SIRE) <b>(Primary research mentor)</b>		Emory Undergraduate Student

b. Residency Program:

1. Consultation Attending Physician, Fellowship Training Program, Infectious Diseases: 2003 – Present
2. Consultation Attending Physician, Medicine Residency Training Program: 2003 – Present

c. Masters' Degree Thesis Committee Membership:

1. Member, MSCR thesis committee for Seema P. Kini, MD, MSc: 2009 – 2011
2. Member, MSCR thesis committee for Jennifer A. Whitaker, MD, MSc: 2010 – 2012
3. Member, MSCR thesis committee for Edward A. Stenehjem, MD, MSc: 2010 – 2012
4. Member, MRSC thesis committee for Ashish Mehta, MD, MSc: 2011 – 2013
5. Member, MSCR thesis committee for Christina Correnti, MD, MSc: 2012 – 2014
6. Member, MSCR thesis committee for Duc Tran, MD: 2013 – 2015
7. Member, MSCR thesis committee for Kobina Wilmot, MD: 2013 – 2015
8. Member, MSCR thesis committee for Seemer Halani, MD: 2016 – 2018

d. Doctorate Dissertation Committee Membership:

1. Member, PhD dissertation for Amanda M. James, PhD: 2010 – 2013
2. Member, PhD dissertation committee for Susie Turkson, MD: 2020 – Present

24. Lectureships, Seminar Invitations, and Visiting Professorships:

a. National and International:

1. Antibiotic treatment of intra-abdominal infections: Western Pennsylvania Hospital Internal Medicine Conference, 2001, Pittsburgh, PA
2. Antimicrobial control Effort, University of Kentucky experience: Wayne Ebrite Young Investigators Conference, 2002, West Point, PA

3. Experience in Academic Clinical Research Career in HIV/AIDS: Connecting with Care: Minority HIV Care Providers. 2005, Miami, FL
4. Pharmacology of Antiretroviral Drugs: Mexican HIV/AIDS opinion leaders. 2006, Atlanta, GA
5. HIV Prevention in Rural African Communities Using Small Media Technology. Center for Diseases Control and Prevention (CDC), Global AIDS Project. 2006, Atlanta, GA
6. HIV-management update: CME Program, Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2007, Tampa, FL
7. Impact of Protein Binding on HIV-protease Inhibitors Pharmacokinetics, Antiviral Clinical Pharmacology Laboratory, University of Alabama, 2007, Birmingham, AL
8. HIV Pharmacotherapy update: University of Alabama at Birmingham Antiviral Clinical Pharmacology Lab, 2010, Birmingham, AL. (The audience included participants from UAB, Emory, University of Minnesota, University of Colorado, and University of Nebraska.)
9. Medical School Curriculum: Integration of Basic and Medical Sciences: Presented to the Medical School Review Committee Constituted by the Federal Ministry of Health, 2011, Abuja, Nigeria
10. Pathogenesis of HIV-induced Bone Loss, Infectious Diseases Seminar, Drexel University, 2011, Philadelphia, PA
11. Translational approach towards understanding the long-term complications of HIV infection with emphasis on the skeletal system: Internal Medicine Ground Rounds, (Visiting Professor), University of Michigan Medical Center, 2012, Ann Arbor, MI
12. Immune dysregulation – a driving force behind HIV associated bone loss. Infectious Diseases Seminar (Visiting Professor). University of North Carolina, 2016
13. Mentoring the next generation of clinician scientists. Addis Abba University, Addis Abba, Ethiopia, June 29, 2018
14. Sex differences in the manifestation of infectious diseases, Ethiopia-Emory TB Research Training Program” (EETB-RTP), Debre Zeit, Ethiopia, July 2018.
15. Recruiting and retaining the hard-to-reach population in clinical research – lessons learned from the Women’s Interagency HIV Study, National CFAR Adelante webinar, July 10, 2018
16. Sex differences in the manifestation of infectious diseases, Ethiopia-Emory TB Research Training Program” (EETB-RTP), Debre Zeit, Ethiopia, July 2019.
17. Long term comorbidities in HIV: the burden and the biology (Visiting Professor), February 2, 2020, Washington University, St. Louis, MO.
18. Biological sex and the outcomes of HIV infection (Visiting Professor), October 29, 2020, Johns Hopkins University, Baltimore, MD.
19. Long term comorbidities in HIV: the burden and the biology (Visiting Professor), April 26, 2021, Rush University, Chicago IL.

b. Regional:

1. Antifungal therapy in HIV/AIDS. Symposium on Antifungal therapy in the New Millennium, 2001, Lexington, Ky
2. HIV/HCV co-infection. Post IDSA/ICAAC symposium, 2002, Lexington, Ky
3. Sex differences in nevirapine clearance. BIRCWH/K-30 retreat, 2002, Lexington, Ky
4. Skin and Soft Tissue Infections, Medical Noon Conference, Medical Center of Columbus, 2004, Columbus, GA

5. Infective Endocarditis; Medicine Ground Round, Medical Center of Columbus, 2004, Columbus, GA
6. Important Drug-drug interaction in HIV management: Medicine noon conference, Medical Center of Columbus, 2006, Columbus, GA
7. Update in HIV Pharmacotherapy: Internal Medicine Grand Rounds, Medical Center of Columbus, 2006, Columbus, GA
8. HIV Management Update: CME Program Atlanta Medical Center, 2006, Atlanta, GA
9. Antiretroviral Resistance: Genotypes & Phenotypes: GA State Ryan White Meeting. 2007, Atlanta, GA
10. HIV/AIDS in 2009; Update and Surgical Issues: Grand Rounds, Morehouse School of Medicine, Department of Surgery, 2009, Atlanta, GA
11. Translation approach towards understanding the impact of HIV-infection in women. Center for Disease Control and Prevention, 2014, Atlanta, GA.

c. Institutional:

1. West Nile Virus: Neurology Ground Rounds, University of Kentucky, 2002, Lexington, Ky
2. Sex differences in the pharmacological effects of the antiretroviral drugs Emory University Infectious Diseases Seminar, 2003, Atlanta, GA
3. Impact of Sex/Gender on the Effects of Antiretroviral Drugs: Grady IDP Physician Assistant Day Lecture, 2003, Atlanta, GA
4. Assisted Reproductive Technique for HIV-infected Couples; Grady Infectious Diseases Program, 2006, Atlanta, GA
5. Antiretroviral Pharmacokinetics, Grady Infectious Diseases Program Didactics, 2007, Atlanta, GA
6. Emerging Challenges in HIV Pharmacotherapy: Emory Medicine Ground Rounds, 2010, Atlanta, GA
7. Long-Term Complications of HIV-disease Management: The Bone. Emory University Infectious Diseases Seminar, 2010, Atlanta, GA
8. K-award to R01 Conversion: Emory University Pediatric Department, 2011, Atlanta, GA
9. Long-Term Complication of HIV-disease Management: The Bone. Emory University Infectious Diseases Seminar, 2011, Atlanta, GA
10. Translational approach towards understanding the long-term complications of HIV infection with emphasis on the skeletal system: Emory Infectious Diseases Seminar, 2012, Atlanta GA
11. Translational approach towards understanding the long-term complications of HIV infection with emphasis on the skeletal system: Atlanta VA Medical Center, 2012, Atlanta, GA
12. Updates – HIV and antiretroviral induced bone loss: Atlanta VA Medical Center, 2013, Atlanta, GA
13. Translational approach towards understanding long-term complications of HIV diseases management – Emory Cardiology Research Seminar, 2013, Atlanta, GA
14. Translational approach towards understanding long-term complications of HIV diseases management – Emory Infectious Diseases Research Seminar, 2013, Atlanta, GA
15. Translational approach towards understanding long-term complications of HIV diseases management – Emory Digestive Division Ground Rounds (Internal Visiting Professor), 2014, Atlanta, GA

16. K-Club – Transition from K-award to independence in research: Emory University Pediatric Dept. 2014, Atlanta, GA
  17. Translational approach towards understanding the long-term complications of HIV infection with emphasis on the skeletal system: Atlanta VA Medical Center, 2014, Atlanta, GA
  18. Pathogenesis of HIV-associated complications, Emory Infectious Disease Division Seminar. 2019, Atlanta, GA
  19. Understanding the pathogenesis of HIV-induced bone loss: Emory University Department of Medicine Research Day: 2019, Atlanta, GA
  20. Long term comorbidities in HIV: the burden and the biology, Emory Pulmonary Division Research Seminar, January 30, 2020.
  21. Protecting Bone Health in Persons Living with HIV, Atlanta VA Research Seminar, May 8, 2020
  22. Biological sex and the outcomes of HIV infection, Emory ID Division Research Seminar, October 29, 2020.
25. Invitations to National/International, Regional, and Institutional Conferences:
- a. National and International:
    1. Understanding the infective process of HIV infection. 8<sup>th</sup> Conference of Association of Nigerian Physicians in the Americas, 2002, Atlanta, GA
    2. Mechanisms of HIV pathogenesis and disease progression in human. 9<sup>th</sup> Conference of Association of Nigerian Physicians in the Americas, 2003, Chicago, IL
    3. HIV Prevention in Rural African Communities Using Small Media Technology. 11<sup>th</sup> Conference of Association of Nigerian Physicians in the Americas, 2005, Nashville, TN
    4. Pharmacokinetic Consideration in Antiretroviral therapy: Invited Speaker at Mexico HIV Congress, 2006, Merida, Mexico
    5. HIV-management update: National Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2007, Atlanta, GA
    6. Invited Participant in the NIAID sponsored forum “Opportunity for improving HIV diagnosis, prevention & access to care in the US: 2007, Bethesda, Maryland
    7. Update in HIV-Disease Management: National Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2008, Tampa, FL
    8. Update in HIV-Disease Management: National Conference of The Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2010, Tampa, FL
    9. HIV and Bone Disease: Mexico National Infectious Diseases Annual Meeting, 2011, Puebla, Mexico
    10. Translational Approach Towards Understanding the Long-Term Complications of HIV Infection. Nigerian Institute of Medical Research Annual Scientific Symposium, 2011, Lagos, Nigeria
    11. Translational Approach Towards Understanding the Long-Term Complications of HIV Infection. National Institute of Allergy and Infectious Disease (NIAID)/Infectious Diseases Society of America (IDSA) Infectious Diseases Research Careers Meeting, 2013, Bethesda, MD
    12. Translational Approach Towards Understanding the Long-term Complications of HIV Infection: Nigerian Institute of Medical Research Annual Scientific Symposium, 2013, Lagos, Nigeria
    13. Finding and Keeping a Mentor: National Institute of Allergy and Infectious Disease (NIAID)/Infectious Diseases Society of America (IDSA) Infectious Diseases Research Careers Meeting, 2013, Bethesda, MD

14. HIV Reservoir in Women – Novel Pharmacokinetics / Pharmacodynamics Approaches: Women Interagency HIV Study/Multicenter AIDS Cohort Study/National Institute of Allergy and Infectious Diseases Joint Annual Meeting, 2014, Bethesda, MD
15. Updates in HIV Disease Management: National Conference, Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2014, Orlando, FL
16. Ebola Virus Disease: Nigerian Institute of Medical Research 2<sup>nd</sup> International Scientific Conference, 2014. Abuja, Nigeria
17. Chronic HIV Infection and End-organ Health – WIHS/NCAB, May 17, 2016, NIH, Bethesda, MD
18. Symposium Session: HIV Co-morbidities – Preventing and Managing End Organ Disease. 2016 IDWEEK, New Orleans, LA
19. The Role of Sex in Infectious Diseases Outcomes: Ethiopia-Emory Research Training Program Annual Conference, June 17, 2018, Addis Ababa, Ethiopia
20. Improving Research Grant Success Rate: Annual Scientific Conference of the Nigeria Institute of Medical Research, November 23, 2018, Abuja, Nigeria
21. End-organ Damage in HIV/AIDS: Lessons Learnt from the Immune-skeletal Interaction: Emory Department of Medicine Research Conference, April 3, 2019
22. HIV-associated Bone Loss: HIV and Aging Conference, April 11, 2019, Atlanta GA
23. ACTG 5257/5260 Weight Gain and Changes in body Composition Analyses: 2019 Annual AIDS Clinical Trials Group Networking Meeting, June 21, 2019, Washington DC
24. Emory-Nigeria HIV Research Training Program in Women’s Health: NIH Fogarty International HIV D43 Annual Meeting, July 21, Bethesda, MD
25. Featured Talk: Long-term Complications of HIV: The Burden and the Biology. Southeastern Regional Clinical & Translational Science Conference, February 27-29, 2020, Callaway Resort and Gardens, GA
26. Sex Differences across the Dystonias: How can we begin to Delineate Mechanisms: 6<sup>th</sup> International Dystonia Symposium, June 4-6, 2020, Dublin, Ireland
27. Cardiovascular Disease in HIV-infected Patients: Emory Women’s Heart Center, 14th Annual Women and Heart Disease Conference, August 15, 2020, Atlanta, GA
28. Conducting Clinical Studies during a Pandemic: Nigeria Institute of Medical Research Conference, November 11, 2020
29. Innovation and Impact: What they are and how to Achieve them: November 5, 2021, National Centers for AIDS Research Annual meeting
30. Featured Talk: Researching COVID to Enhance Recovery: The RECOVER Prospective Cohort Stud 2022 Southeast Regional Clinical and Translational Science Conference: March 3, 2022.
31. NIH RECOVER Webinar: Post-acute sequelae of COVID-19 in Adults:

b. Regional:

- I. Individualized HIV Treatment Strategy – State of the Art Lecture: Southern Society for Clinical Investigation Annual Meeting, 2014, New Orleans, LA

26. Abstract Presentations at National/International, Regional, and Institutional Conferences: March 22, 2022.

a. National and International:



1. Sitwala K\*, Faulkner N, Mor-Vaknin N, **Ofotokun I**, Adams B, Markovitz D. Expression and Mechanism of Action of DEK. Poster presented at the International Congress of Immunology. 2001.
2. **Ofotokun I\***, Rapp RP, Empey KL, Martin C, Evans ME, Armistead JA. Result of a four-year effort to control the use of antimicrobial agents at a university-affiliated hospital. 40<sup>th</sup> IDSA meeting, Chicago Oct 22-27, 2002. Poster Abstract 601.
3. **Ofotokun I\***, Pomeroy C, McNamara P. Sex difference in nevirapine clearance. 41<sup>st</sup> IDSA meeting, San Diego Oct 9-12, 2003. Poster Abstract 87.
4. O'Neil KL\*, **Ofotokun I**, Googe H, Patel M. Evaluation of the efficacy and safety of enfuvirtide therapy in HIV patients at Grady Health System, 39th ASHP Midyear Clinical Meeting, Orlando Florida Dec 5-9, 2004. Poster Abstract PR 76
5. **Ofotokun I\***, Smithson S, Lu C, Easley KA, Lennox JL. Association between Hepatitis B and C Sero-status Antiretroviral Related Liver Enzymes Elevation and Immune Reconstitution Among Treatment Naïve HIV-Infected Patients. Presented at the 43<sup>rd</sup> annual meeting of the Infectious Diseases Society of America. Oct. 6-9, 2005, San Francisco. Poster Abstract #876
6. **Ofotokun I\***, Binongo J.N.G., Favaloro-Sabatier J., Easley K.A., Lennox J.L., Kane M. Knowledge, Attitudes, Beliefs and Practices of Residents of Three Rural African Communities. XVI International AIDS Conference, Toronto 13-18 August 2006: Poster Abstract: A-011-0160-11562.
7. **Ofotokun I\***, Kane M, Binongo J, Binongo J.N.G., Favaloro-Sabatier J. HIV/AIDS Education Program Using Small Media-based Technology for Oral Communicators at the Community Level to Enhance HIV/AIDS Awareness. The 2006 HIV/AIDS Implementers' Meeting in Durban, South Africa, June 12-15, 2006: Abstract #C9/124. Oral Presentation.
8. **Ofotokun I\***, Chuck SK, Palau M, Binongo, Acosta JE, Lennox JL. Lack of Sex Differences in Once Daily Lopinavir/ritonavir (LPV/r) Pharmacokinetic (PK) Profile. Program and Abstracts of the Eighth International Congress on Drug Therapy in HIV Infection. 12-16 November 2006. Glasgow, UK. Poster Abstract #296.
9. **Ofotokun I\***, Acosta E, Lennox J. Pharmacokinetics of an indinavir/ritonavir/fos-amprenavir regimen in HIV-infected individuals. Poster presentation at the 4<sup>th</sup> IAS Conference, Sydney, Australia, July 22-25, 2007.
10. **Ofotokun I\***, Chuck S, Rivas M, Rode R. Switching from lopinavir/ritonavir (LPV/r) soft gel capsule (SGC) to Tablet formulation improves tolerability. Poster Abstract and Program of the 45<sup>th</sup> annual meeting of the Infectious Diseases Society of America, Oct 4 – 7, 2007, San Diego.
11. King JR\*, **Ofotokun I**, Rivas M, Johnson VA, Acosta EP. Integrating Pharmacokinetics and Antiretroviral Resistance Testing in Clinical HIV-1 Management. Poster Abstract, 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb. 3 – 6, 2008.
12. **Ofotokun I\***, Lennox L, Eaton M, Ritchie J, Acosta E. Immune Activation Mediated Change in the Plasma Binding Protein Alpha-1-Acid Glycoprotein Alters Plasma Lopinavir Concentrations. Program and Abstracts of the 17<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, at Moscone Center West in San Francisco, CA. Poster Abstract #N-105.
13. **Ofotokun I\***, Lennox L, Long M, Ritchie J, Acosta E. Circulating levels of alpha-1-acid glycoprotein do not affect free lopinavir pharmacokinetic profile. Program and Abstracts of the 11<sup>th</sup> International Workshop on Clinical Pharmacology of HIV Therapy; 7 – 9 April 2010, Sorrento, Italy. Poster Abstract #44.
14. **Ofotokun I\***, Weitzmann NM, Vunnava A, Sheth A, Villinger F, Zhou J, Williams EB, Sanford SE, Rivas M, and Lennox JL. HAART-Induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS. Oral Presentation in the Program and Abstracts of the 18<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February 27-March 2 2011 at Hynes Convention Center in Boston, MA. Abstract #O-102.

15. Acosta EP\*, Limoli KL, Trinh L, Parkin NT, King JR, Weidler J, **Ofotokun I**, and Petropoulos CJ. Novel method to assess antiretroviral target trough concentrations using *in vitro* susceptibility data. Poster Abstracts, the 18<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, at Hynes Convention Center in Boston, MA. Abstract #N-145.
16. Sheth AN\*, Evans-Strickfaden T, Martin A, Gatcliffe C, Adesoye A, Omondi M, Haaland R, Lupo LD, Easley KA, Pau CP, Hart C, **Ofotokun I**. Genital secretions of HIV-1 infected women on effective antiretroviral therapy contain high drug concentrations and low amounts of cell-free virus. Oral Presentation of the Program and Abstracts of the 6<sup>th</sup> International AIDS Society Conference, July 17 – 23, 2011. Abstract #290.
17. **Ofotokun I\***, Sheth AN, Easley KA, Shenvi N, White K, Eaton M, Del Rio C, Lennox JL. Switching Antiretroviral Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-infected Patients is Safe and Well Tolerated (The KITE Study). Poster Abstract, 6<sup>th</sup> International AIDS Society Conference, July 17 – 23, 2011. Abstract # CDB272.
18. McIntosh E\*, Vunnavu A, Lennox JL, Weitzmann MN, and **Ofotokun I**. Suppression of formation threatens delayed-phase bone loss in virologically HIV+ individuals on chronic ART. Program and Abstracts of the 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, March 3-5, 2012, Seattle, WA. Poster Abstract #877.
19. James A\*, King K, **Ofotokun I**, Sheth A, and Acosta E. Determination of Tenofovir (TFV) and Emtricitabine (FTC) Uptake *in vitro* with Non-Monocytic Genital Tract Cells. Program and Abstracts of the 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, March 3-5, 2012, Seattle, WA. Poster Abstract #586.
20. Sheth AN, **Ofotokun I\***, Buchacz K, Armon C, Baker R, Brooks J, , Palella F. Antiretroviral regimen durability in treatment-naïve and treatment-experienced patients by year of treatment initiation, United States, 1996–2008. Poster Abstract, XIX International AIDS Conference (AIDS 2012), to be held in Washington, D.C., 22-27 July 2012.
21. Titanji K\*, Vunnavu A, Sheth A, Lennox J, Weitzmann MN, **Ofotokun I**. B Cell Dysregulation Promotes HIV-induced Bone Loss. 20th Conference of Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Poster Abstract.
22. Landovitz RJ\*, Tran TTT, Cohn SE, **Ofotokun I**, Lennox JL, Currier JS, Ribaud HJ. HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. 20th Conference of Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Poster Abstract.
23. Zaeh S\*, Kempker R, Stenehjem E, Blumberg HM, **Ofotokun I**, Tenna A. Improving Tuberculosis Screening and Isoniazid Preventative Therapy in an HIV Clinic in Addis Ababa, Ethiopia. 20th Conference of Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Poster Abstract.
24. Delille CA\*, Pruett ST, Marconi VC, Armstrong WS, Lennox JL, Arrendale RF, Sheth AN, Easley KA, and **Ofotokun I**. Degree of Plasma Protein Binding Affects Central Nervous System (CNS) Penetration of the HIV-1 Protease Inhibitors. Oral Abstract, 2<sup>nd</sup> Annual NIAID/IDSA Research Careers Meeting. June 6-8, 2013. Bethesda, Maryland.
25. Wang K\*, D'Argenio D, Sheth A, Lennox JL, Acosta EP, and **Ofotokun I**. Integrated Model of Lopinavir Pharmacokinetics and HIV-1 Viral Dynamics: The Role of  $\alpha$ -1-acid Glycoprotein Binding. 2013 ACoP, Poster Abstract, Fort Lauderdale, FL.
26. Wang K\*, D'Argenio DZ, Acosta EP, Sheth AN, Delille C, Lennox JL, Kerstner-wood C, and **Ofotokun I**. Integrated population pharmacokinetic and viral dynamic modeling of lopinavir/ritonavir in HIV-1 treatment naïve patients. 4th International Symposium in Quantitative Pharmacology, Beijing, China, November 1-3, 2013 (Janssen Poster Excellence Award, First Prize).

27. Landovitz RJ\*, Ribaldo HJ, **Ofotokun I**, Wang H, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, and Lennox JL and the A5257 Study Team. Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTC/tenofovir. 21st Conference of Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston. Oral abstract 85.
28. **Ofotokun I\***, Ribaldo H, Na L, McComsey G, Cohn S, Godfrey C, Sagar M, Aweeka F, Lennox J, Currier J. Darunavir or atazanavir versus raltegravir lipid changes are unlinked to ritonavir exposure: ACTG 5257. 21st Conference of Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston. Poster abstract 746.
29. Larson KB, Wang K, James AM, **Otofokun I\***, Sheth A, Delille C, Vunnava A, Acosta EP. Population analysis of tenofovir plasma and intracellular pharmacokinetics in female HIV-1 seropositive patients. 15<sup>th</sup> Antiretroviral PK Workshop, Washington DC, 2014. Oral abstract.
30. Delille CA\*, Burk RD, Palefsky JM, Massad LS, Reimers L, Minkoff H, Xie X, D'Souza G, Xue X, Colie C, Anastos K, Dugan KB, Wingood G, Strickler HD, **Ofotokun I**. Lopinavir Use and Human Papillomavirus (HPV) Infection in HIV Positive Women. (Poster). 29<sup>th</sup> International Papillomavirus Conference. August 21-25, 2014. Seattle, Washington.
31. Aguirre AJ, Mehta C, **Ofotokun I\***, Gandhi M, Hussen SA, Merenstein D, Kashuba AD, Anastos K, Kempf MC, Golub ET, Greenblatt RM, Dehovitz JA, Milam J<sup>1</sup>, Cohen MH<sup>1</sup>, Sheth. The prevalence of persistent low-level viremia and virologic failure among a cohort of HIV-infected women on antiretroviral therapy. Poster Abstract, CFAR Symposium on HIV Research in Women. December 8-9, 2014. Buffalo, NY.
32. Natanzon Y\*, Zhu X, Morris N Sharma A, Gustafson D, Liu CL, Greenblatt R, Pearce L, Adeyemi O, Irvin R, Dykxhoorn D, **Ofotokun I**, Floris-Moore M, Pierce C. Preliminary Candidate Gene Analysis In The Women'S Interagency HIV Study Shows Pleiotropic Effect Of APOB4 And Novel Associations Of BMP4 And NOS3 With Metabolic Syndrome Traits. HYPERTENSION Volume: 64 Supplement: 1 Meeting Abstract: 274 Published: SEP 2014
33. Vardhanabhuti S\*, Ribaldo H, Raphael Landovitz R, **Ofotokun I**, Lennox J, Currier J, Olson L, Haas D. *UGT1A1* Genotype Predicts Bilirubin-related Discontinuation of Atazanavir/Ritonavir. 22<sup>nd</sup> Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2015
34. Swaims A\*; Evans-Strickfaden T; Lupo LD; Aguirre A; Sheth S; **Ofotokun I**; Hart C; Haaland R. Progesterone Increases are Associated With HIV Susceptibility Factors in Women. 22<sup>nd</sup> Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2015
35. Sarkar M\*, Dodge JL, Greenblatt Ruth, Kuniholm MH, Dehovitz J, Plankey M, Kovacs A, French A, Seaberg EC, **Ofotokun I**, Fischl M, Overton ET, Kelly E, Bacchetti P, Peters MG. Reproductive Aging, Independent of Chronologic Age, Is Associated with Accelerated Fibrosis Progression in HIV/HCV Co-Infected Women. Conference: 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) Location: San Francisco, CA Date: NOV 13-17, 2015, Sponsor(s): Amer Assoc Study Liver Dis. HEPATOLOGY Volume: 62 Special Issue: SI Supplement: 1 Pages: 914A-915A Meeting Abstract: 1444 Published: OCT 2015
36. **Ofotokun I\***, Titanji K, Vunnava V, Foster A, Sheth AN, Lahiri CD, Lennox JL, Knezevic A, Easley KA, Weitzmann MN. A Single Dose Zoledronic Acid Prevents Antiretroviral-Induced Bone Loss. Oral presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.
37. Ribaldo HJ\*, Landovitz RJ, Na LH, Lennox JL, **Ofotokun I**, Cohn SE, Kuritzkes D, Currier JS for the ACTG A5257 Study Team. Gender and Racial Disparities in Initial Antiretroviral Treatment Outcome: ACTG A5257. Poster presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.

38. Landovitz JL\*, Tran TT, Cohn SE, **Ofotokun I**, Bishopric GA, Lennox JL, Currier JS, Ribaldo JJ. Perception of Infectiousness in HIV-Infected Persons After Initiating ART: ACTG A5257. Oral presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.
39. Chan ES\*, Mirmonsef P, Brown TT, Landay AL, **Ofotokun I**, Weitzmann MN, Martinson J, Plants J, Ribaldo HJ, Taiwo B. Immunologic Effects of Maraviroc vs Tenofovir and Associations With Bone Loss. Poster presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.
40. Sheth AN\*, Iyer, SS, Sabula MJ, Brown NL, Haddad LB, Mehta CB, Amara RR, **Ofotokun I**. The Effect of Sampling Strategy on Phenotypic Characteristics of HIV Target Cells in the Female Genital Tract. Conference: Conference on HIV Research for Prevention (HIV R4P) Location: Chicago, IL Date: OCT 17-20, 2016. AIDS RESEARCH AND HUMAN RETROVIRUSES Volume: 32 Supplement: 1 Pages: 306-306 Meeting Abstract: P18.03 Published: OCT 2016
41. Bhagwat P\*, **Ofotokun I**, McComsey GA, Brown TT, Moser CB, Ribaldo HJ, Sugar CA, Currier JS. Measurement of Abdominal Fat Changes in HIV-Infected Individuals Initiating Therapy. Poster presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.
42. Donahue Carlson R\*, Sheth AN, Read T, Frisch M, Mehta C, Martin A, Evans-Strickfaden T, Haaland RE, Pau C, Kraft C, Hart CE, **Ofotokun I**. The female genital tract microbiome is associated with vaginal antiretroviral drug concentrations in HIV-infected women on antiretroviral therapy. Poster Presentation at the 21<sup>st</sup> International AIDS Conference, Durban, South Africa, July 18-22, 2016, # A-792-0175-02699
43. Haddad LB\*, Wall K, C. Christina Mehta CC, Elizabeth Golub E, Rahangdale L, Kempf M, Karim R, Wright R, Minkoff H, Cohen M, Kassaye S, Cohan D, **Ofotokun I**, Cohn SE. Trends and predictors of pregnancy and abortion rates among HIV infected and uninfected women enrolled in Women's Interagency HIV study (WIHS): 1994-2012. Poster Presentation at the 21<sup>st</sup> International AIDS Conference, Durban, South Africa, July 18-22, 2016, # A-792-0342-07247
44. Titanji K, Vunnavu A, Sheth AN, Lahiri CD, Lennox JL, Foster A, Weitzmann MN, **Ofotokun I**\*. Contribution of T cells to RANKL/OPG imbalance and bone loss in HIV infection. Poster Presentation at the 21<sup>st</sup> International AIDS Conference, Durban, South Africa, July 18-22, 2016, # A-792-0127-08875
45. Moran CA\*, Vunnavu A, Sheth AN, Mehta C, Tien P, Plankey M, Golub ET, Quyyumi A, Kaplan RC, **Ofotokun I**. CRP predicts subclinical CVD progression in HIV- but not HIV+ women. Abstract #629, poster presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.
46. **Ofotokun I**\*, Titanji K, Vunnavu A, Foster A, Sheth AN, Lahiri CD, Lennox JL, Knezevic A, Easley KA, M. Weitzmann MN. Antiretroviral bone loss is durably suppressed by a dose of zoledronic acid. Abstract #684, poster presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.
47. Bhagwat P\*, **Ofotokun I**, McComsey GA, Brown T, Moser C, Sugar CA, Currier JS. Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation. Abstract #695, oral presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.
48. Weiser S\*, Sheira LA, Palar K, Wilson T, Metsch L, Adimora A, **Ofotokun I**, Wentz E, Tien P, Frongillo EA. Food insecurity and HIV treatment outcomes in the Women's Interagency HIV Study. Abstract #913, poster presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.
49. Haddad LB\*, Kohlmeier AS, Haaland R, Brown N, Lupo D, Mehta C, Sheth AN, Titanji K, Hart C, **Ofotokun I**. Changes in genital-tract HIV target cells with three progestin-based contraceptives. Abstract #943, oral presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.

50. Lahiri CD\*, Brown N, Chien H, Vunnava A, Ryan K, Acosta EP, Sheth AN, Ingersoll J, **Ofotokun I**. HIV RNA persists in rectal tissue despite virological suppression in blood plasma with dolutegravir-based combination antiretroviral therapy in treatment-naïve patients. Abstract, oral presentation at International AIDS Conference, Paris, France, 2017.
51. Collins LF\*, Sheth AN, Moran CA, Ward L, Shenvi N, Titjani K, Abraham R, Tisdale T, Nguyen T, Easley K, Lennox J, Weitzmann MN, **Ofotokun I**. Bone turnover biomarkers may discriminate low bone mineral density in persons living with HIV. Georgia Clinical & Translational Science Alliance, Callaway Gardens, GA, February 2019. (poster)
52. Collins LF\*, Sheth AN, Moran CA, Ward L, Shenvi N, Titjani K, Abraham R, Tisdale T, Nguyen T, Easley K, Lennox J, Weitzmann MN, **Ofotokun I**. Bone turnover biomarkers may discriminate low bone mineral density in persons living with HIV. Translational Science, Washington DC, March 2019. (poster)
53. Collins LF\*, Sheth AN, Mehta CC, Golub ET, Tien PC, Anastos K, French AL, Kassaye S, Taylor T, Kempf MC, Fischl MA, Adimora AA, Palella FJ, **Ofotokun I**. Women with HIV have high overall burden and early accrual of non-AIDS Comorbidities. *Accepted for poster presentation at the Conference on Retroviruses and Opportunistic Infections, Boston, MA, March 2020.*

b. Regional:

1. McIntosh E\*, Vunnava A, Lennox JL, Weitzmann MN, and **Ofotokun I**. Suppression of formation threatens delayed-phase bone loss in virologically HIV+ individuals on chronic ART. Oral presentation. 2012 Southern Regional Meetings, New Orleans, LA.
2. Zaeh S\*, Kempker R, Stenehjem E, Blumberg HM, **Ofotokun I**, Tenna A. Improving Tuberculosis Screening and Isoniazid Preventative Therapy in an HIV Clinic in Addis Ababa, Ethiopia. Oral presentation. 2013 Southern Regional Meetings, New Orleans, LA.
3. Delille CA\*, Burk RD, Palefsky JM, Massad LS, Reimers L, Minkoff H, Xie X, D'Souza G, Xue X, Colie C, Anastos K, Dugan KB\*, Wingood G, Strickler HD, **Ofotokun I**. Lopinavir Use and Human Papillomavirus (HPV) Infection in HIV Positive Women. Poster presentation. 2015 Southern Regional Meetings, February 26-28, New Orleans, LA.

c. Institutional:

1. **Ofotokun I\***, Lennox L, Long M, Ritchie J, Acosta E. Circulating levels of alpha-1-acid glycoprotein do not affect free lopinavir pharmacokinetic profile. Poster presentation. 2010 Department of Medicine Research Day, Emory University, Atlanta, GA.
2. **Ofotokun I\***, Weitzmann NM, Vunnava A, Sheth A, Villinger F, Zhou J, Williams EB, Sanford SE, Rivas M, and Lennox JL. HAART-Induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS. Poster presentation. 2011 Department of Medicine Research Day, Emory University, Atlanta, GA.
3. McIntosh E\*, Vunnava A, Lennox JL, Weitzmann MN, and **Ofotokun I**. Suppression of formation threatens delayed-phase bone loss in virologically HIV+ individuals on chronic ART. Poster presentation. 2012 Medical Students Research Day, Emory University, Atlanta, GA.
4. Zaeh S\*, Kempker R, Stenehjem E, Blumberg HM, **Ofotokun I**, Tenna A. Improving Tuberculosis Screening and Isoniazid Preventative Therapy in an HIV Clinic in Addis Ababa, Ethiopia. Oral presentation. 2013 Medical Students Research Day, Emory University, Atlanta, GA.
5. Delille CA\*, Pruett ST, Marconi VC, Armstrong WS, Lennox JL, Arrendale RF, Sheth AN, Easley kA, and **Ofotokun I**. Degree of Plasma Protein Binding Affects Central Nervous System (CNS) Penetration of the HIV-1 Protease Inhibitors. Poster presentation. 2013 Department of Medicine Research Day, Emory University, Atlanta, GA.
6. Delille CA, Dugan KB\*, Burk RD, Palefsky JM, Massad LS, Reimers L, Minkoff H, Xie X, D'Souza G, Xue X, Colie C, Anastos K, Wingood G, Strickler HD, **Ofotokun I**. Lopinavir Use and Human

27. Research Focus:

My research is focused on characterizing the burden and the pathogenesis of HIV associated age-related co-morbidities, particularly as they affect women, with the goal of promoting healthy aging. I am also committed to research education and career development for the next generation of clinical and translational researchers.

28. Grant Support:

Active:

- |    |   |                                |                       |
|----|---|--------------------------------|-----------------------|
| 1. | R01 AR070091-04 (Ofotokun, Weitzmann)   | 04/2021 – 03/2026<br>NIH/NIAMS | 1.2 CM<br>\$682,058   |
|    | <b>Predictor of Antiretroviral Immunoreconstitution Bone Loss – the Gut and Microbiome:</b> Bone loss is a severe complication of HIV infection that is dramatically exacerbated by antiretroviral therapy (ART). Defining the mechanisms by which ART induces bone loss is necessary to devise novel therapeutic strategies to preserve and restore bone mass to prevent bone fractures in aging people living with HIV/ART.<br>Role: Contact Principal Investigator |                                |                       |
| 2. | 1OT2HL162054 Atlanta Hub (Ofotokun, Patzer, Pemu)   | 10/2021 – 05/2025              | 3.6 CM<br>\$9,537,735 |
|    | <b>Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: SARS-CoV-2 Recovery Cohort:</b> A multisite national cohort study aimed at understanding the burden, the disease course and the trajectory of recovery and the pathobiology of post-acute sequelae of COVID-19 in the US<br>Role: Atlanta Hub Contact Principal Investigator   |                                |                       |
| 3. | U01HL146241 (Ofotokun, Sheth, Wingood)  | 04/2019 – 03/2026              | 1.9 CM<br>\$3,595,174 |
|    | <b>Atlanta MACS/WIHS Combined Cohort Study Clinical Research Site:</b> The purpose of this proposal is to recruit and retain a diverse cohort of eligible women and men representative of the U.S. HIV/AIDS epidemic with the aim of evaluating the long-term impact of HIV infection in this population.<br>Role: Contact Principal Investigator   |                                |                       |
| 4. | U54AG062334 (Ofotokun, Lahiri)  | 09/2018 – 05/2023              | 2.4 CM<br>\$1,498,219 |
|    | <b>Emory Specialized Center of Research Excellence (SCORE) on Sex Differences:</b> The overarching goal of the Emory SCORE is to advance the quality of women’s health research by leveraging the rich, collaborative and interdisciplinary research environment at Emory University to grow NIH and other extramurally funded research in women’s health.<br>Role: Multiple Principal Investigator   |                                |                       |
| 5. | 2K12 HD085850 (Ofotokun, Sterk)   | 09/2015 – 04/2025              | 1.2 CM<br>\$635,266   |
|    | <b>Emory BIRCWH Program:</b> This program will provide career development training and support for early career investigators interested in women’s health research and sex/gender science. The ultimate goal is to develop the next generation of leaders in women’s health research.<br>Role: Contact Principal Investigator  |                                |                       |
| 6. | D43TW010934 (Ofotokun)  | 04/2019 – 03/2024              | 1.2 CM<br>\$300,612   |
|    | <b>Emory-Nigeria HIV Research Training Program (EN-RTP):</b> The overall goal is to leverage the expertise at Emory University and the three partnering Nigerian institutions to enhance predominantly in-country didactic and mentored research training for Nigerian early career trainees.<br>Role: Contact Principal Investigator   |                                |                       |

- |     |  |                   |                        |
|-----|--|-------------------|------------------------|
| 7.  | R38AL140299-02 (Ofotokun, Rouphael)<br>NIH/NIAID   | 07/2018 – 06/2022 | 0.12 CM<br>\$344,760   |
|     | <b>Emory StARR Program (R38 Research Training Program):</b> The overarching goal of the Emory R38 RTP is to leverage the rich infrastructure and the interdisciplinary research environment at Emory to provide clinical and translational research training for resident physicians.<br>Role: Contact Principal Investigator  |                   |                        |
| 8.  | 4U01 AI069919 (Jaquet, Ekuevi, Ofotokun)<br>NIH/NIAID  | 07/2021 – 06/2025 | 0.24 CM<br>\$1,705,000 |
|     | <b>International epidemiology database to evaluate AIDS (leDEA) West Africa:</b><br>A collaboration with the University of Bordeaux, France, to establish an leDEA West Africa site in Lagos, Nigeria and contribute to the scientific and career development agenda of the leDEA consortium through participation in regional and global activities of leDEA in all 7 regions.<br>Role: Multiple Principal Investigation  |                   |                        |
| 9.  | R01 AR070091-04 (Weitzmann, Ofotokun)<br>NIH/NIAMS   | 09/2016 – 08/2021 | 1.2 CM<br>\$606,817    |
|     | <b>IL-4, a key regulator of bone turnover in HIV and ART:</b> This project quantifies the role of IL-4 in the altered B-cell OPG and RANKL and enhanced bone resorption associated with ART-naïve HIV-infected subjects and employs state-of-the-art animal models to define the sources and mechanistic functions of IL-4 in the maintenance of physiological bone mass by direct actions on osteoclasts and indirect actions through OPG.<br>Role: Multiple Principal Investigator |                   |                        |
| 10. | KL2 TR002381-03 (Blumberg)<br>NIH/NCATS  | 09/2017 - 06/2022 | 1.2 CM<br>\$1,305,199  |
|     | <b>Georgia CTSA Institutional Career Development (KL2):</b> This program is aimed at supporting and fostering the career development of junior investigators interested in clinical and translational research.<br>Role: Co-Director, KL2 Program  |                   |                        |
| 11. | P30 AI050409-08 (del Rio)<br>NIH/NIAID   | 08/2012 – 07/2022 | 0.24 CM<br>\$305,378   |
|     | <b>Emory University Center for AIDS Research (CFAR):</b> This award supports the Emory CFAR in all domains of HIV/AIDS research.<br>Role: Co-Director Emory CFAR Clinical Core   |                   |                        |
| 12. | UM1 AI069418-06 (Lennox)<br>NIH/NIAID  | 12/2020 – 11/2027 | 0.12 CM<br>\$2,300,000 |
|     | <b>HIV/AIDS CTU:</b> The goal of this project is to establish a clinical trials site to perform studies in human volunteers in conjunction with various networks established by the NIAID and other agencies.<br>Role: Co-Investigator   |                   |                        |
| 13. | UM1AI148684-01 (Stephens, Neuzil)<br>NIH/NIAID   | 12/2019 – 11/2026 | 1.2 CM<br>\$2,372,307  |
|     | <b>Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG):</b> The emphasis—and strength—of the IDCRCLG is to facilitate, plan and implement clinical research for respiratory and enteric infections, malaria and other tropical diseases, and sexually transmitted infections (STIs), as well as to respond to emerging infectious diseases.<br>Role: Co-Chair, Mentorship, Training, Education Key Function Committee                                |                   |                        |

### Pending

- |    |  |                   |                        |
|----|--|-------------------|------------------------|
| 1. | U54CA272152 (Arriola, Meltzer, Ofotokun)<br>NIH/OD/NCI   | 07/2022 – 06/2027 | 0.12 CM<br>\$3,730,188 |
|    | <b>Emory Leads in Equity, Values, and Transformational Excellence (ELEVATE):</b> This program will build a community of diverse biomedical scientists through the hiring and multi-tiered support of a |                   |                        |

large, 20-strong cohort of early-career faculty with a demonstrated track record of inclusive excellence work. The ELEVATE program will foster sustainable institutional culture change, promote institutional inclusive excellence, and support measurable faculty development, mentoring, sponsorship, and promotion efforts.  
 Role: Multiple Principal Investigator

**Previous Support:**

1. R01AI058696 (Acosta) 2004 – 2008 1.2 CM  
 NIAID \$125,000  
Integrating Pharmacokinetics and Antiretroviral Resistance Testing: The primary goal of this project is to establish prospective validity and short-term clinical efficacy of a novel methodology that integrates antiretroviral pharmacokinetic information and drug susceptibility data in order to effectively treat highly treatment resistant patients.  
 Role: Co-investigator
2. ACTG (Ofotokun) 2004 – 2006 3.8 CM  
 NIAID Total Cost: \$92,000  
Adult AIDS Clinical Trials Group Minority Training Fellowship Program (MATP): This a mentor-oriented HIV/AIDS clinical research training award under the mentorship of Dr. Lennox.  
 Role: Trainee
3. Office of Global AIDS Coordinator: 2005 – 2006 3.8CM  
 PEPFAR Total Cost: \$183,538  
Integrating Digital-Audio Technology and Orality-Based HIV Education to Enhance Awareness: The goal of this project is to scientifically evaluate Voice for Humanity’s rural HIV awareness campaign in Africa.  
 Role: Principal Investigator for Monitoring and Evaluation
4. Emory Medical Care Foundation (Ofotokun) 2005 – 2007  
 Total Cost: \$24,675  
Pharmacokinetics of an Indinavir/Ritonavir/Amprenavir: The primary goal of this project is to evaluate the pharmacokinetic interaction between these protease inhibitors when concomitantly administered to HIV-infected patients.  
 Role: Principal Investigator
5. Abbott Laboratories Inc. Ofotokun (PI) 2005 – 2008 0.60 CM  
 Total Cost: \$98,000  
Once Daily Lopinavir/Ritonavir: A 24-hour Pharmacokinetic Profile to Evaluate Sex Differences: The major goal of this project is to evaluate the sex differences in lopinavir/ritonavir pharmacokinetics.  
 Role: Principal Investigator
6. K12 RR017643 (Stephens) 2006 – 2007 9.0 CM  
 NIH Annual Cost: \$120,000  
Impact of Plasma  $\alpha$ -1-acid Glycoprotein Variability on Free (unbound) Lopinavir Pharmacokinetics in HIV-Infected Subjects: The goal of this program is to enable recipients to develop an academic career in clinical research under a protected mentored environment.  
 Role: Trainee/Principal Investigator
7. NIH K23 A1073119 (Ofotokun) 2007 – 2012 9.0 CM  
 NIAID Annual Cost: \$128,007  
Impact of Plasma  $\alpha$ -1-acid Glycoprotein Variability on Lopinavir Levels: The goal of this program is to enable recipients to develop an academic career in clinical research under a protected mentored environment.  
 Role: Principal Investigator



- |     |   |                            |                      |
|-----|---|----------------------------|----------------------|
| 8.  | Merck/Abbott Laboratories Inc. (Ofotokun)   | 2007 – 2012<br>Total Cost  | 0.12 CM<br>\$600,000 |
|     | <u>A Pilot Study to Assess the Safety, Efficacy, and Pharmacokinetic Profile of a Switch in Antiretroviral Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-infected Patients</u>  |                            |                      |
|     | Role: Principal Investigator  |                            |                      |
| 9.  | R01 AR059363 (Weitzmann, Ofotokun)<br>NIH/NIAMS   | 2009 – 2015<br>Annual cost | 2.7 CM<br>\$639,646  |
|     | <u>Effect of HIV Infection and HAART on Bone Homeostasis: This study will investigate the impact of HIV/HAART on Bone Homeostasis and examine the correlation between B cell and T cell OPG and/or RANKL production in treatment-naïve HIV-infected patients, with indices of bone turnover and structure.</u>  |                            |                      |
|     | Role: Principal Investigator (MPI)  |                            |                      |
| 10. | Bill & Melinda Gates Foundation (Acosta)  | 2009 – 2010<br>Total cost  | 1.2 CM<br>\$244,110  |
|     | <u>Antiretroviral Quantitation and Modeling in the Female Genital Tract: The goal of this project is to generate predictive PK models to guide the use of antiretrovirals in HIV pre-exposure prophylaxis.</u>  |                            |                      |
|     | Role: Co-Principal Investigator   |                            |                      |
| 11. | R01AG040013 (Ofotokun)<br>NIH/NIA   | 2011 – 2017<br>Annual cost | 2.4 CM<br>\$595,426  |
|     | <u>Bone Loss and Immune Reconstitution in HIV/AIDS: Osteoporosis is a well-known complication of HAART, but the mechanisms remain poorly defined. This proposal will investigate a new hypothesis exploring how immune reconstitution following HAART initiation leads to rapid bone loss. It will also test and evaluate the effects of an acute anti-resorptive therapy on preventing skeletal deterioration.</u> |                            |                      |
|     | Role: Contact Principal Investigator  |                            |                      |
| 12. | R01 NR012923 (Holstad)<br>NIH/NINR  | 2012 – 2016<br>Annual Cost | 0.9 CM<br>\$656,958  |
|     | <u>An Audio Music Self-Management Program to Improve ART Adherence in Rural Georgia:</u>  |                            |                      |
|     | The goal of this project is to evaluate the efficacy of an audio program designed to enhance knowledge, motivation and self-efficacy about ART adherence among HIV-infected patients in rural communities.  |                            |                      |
|     | Role: Co-Investigator   |                            |                      |
| 13. | Bristol-Myers Squibb. (Ofotokun)  | 2012 – 2016<br>Total Cost  | 0.12 CM<br>\$261,744 |
|     | <u>Impact of plasma protein binding on CNS free drug penetration for HIV-1 protease inhibitors: The role of the project is to assess the impact of plasma binding protein on CNS compartmentalization of the HIV-1 protease inhibitors.</u>   |                            |                      |
|     | Role: Principal Investigator  |                            |                      |
| 14. | R56 HL126558 (Quyuyumi/Ofotokun)<br>NIH/NHLBI   | 2014 – 2016<br>Annual Cost | 2.40 CM<br>\$761,272 |
|     | <u>Injury and Repair Factors Promoting Atherosclerosis in HIV: The results of this project will increase the understanding of molecular and regenerative pathways and their interactions in HIV-infected subjects as well as their influence on risk of presence and progression of vascular disease in this population.</u>  |                            |                      |
|     | Role: Multiple Principal Investigator   |                            |                      |
| 15. | R21 AI112362 (Gandhi)<br>NIAID  | 2014–2016<br>Annual Cost   | 0.60 CM<br>\$189,000 |
|     | <u>Hair measures to assess adherence and explain outcomes in an HIV clinical trial: This proposal</u>   |                            |                      |

seeks to extend the approach of using hair antiretrovirals levels to monitor adherence and exposure to the HIV treatment trial setting in partnership with the ACTG to further test our methodology in a clinical trial which exposes randomized treatment-naive patients to 3 NNRTI-sparing regimens.

Role: Co-investigator

16. U01AI103408 (Ofotokun) 2013 – 2018 2.4 CM  
NIH/NIAID Annual Cost \$2,519,163  
Emory WIHS CRS - Longitudinal Cohort: The purpose of this proposal is to recruit and retain a diverse cohort of eligible women representative of the local epidemic in the state of Georgia into the Women Interagency HIV Study Cohort.  
Role: Principal Investigator (PI)
17. K12 HD085850 (Ofotokun/Sterk) 2020 – 2025 1.2 CM  
NICHD \$466,643  
Emory BIRCWH Program: This program will provide career development training and support for early career investigators interested in women's health research and sex/gender science. The ultimate goal is to develop the next generation of leaders in women's health research.  
Role: PI/Program Director
18. R01AR068157 (Weitzmann/Ofotokun) 2015 – 2020 0.12 CM  
NIH/NIAMS Annual Cost \$654,899  
**Accelerated Bone Loss in Aging HIV-infected Individuals**: Bone loss is an established complication of aging, HIV/AIDS and ART. This project will improve our understanding of the mechanisms involved and how HIV/AIDS and ART affect bone loss in the context of aging. This knowledge is necessary to devise novel therapeutic strategies to preserve and restore bone mass to prevent bone fracture.  
Role: Multiple Principal Investigator

29. Bibliography:

a. **Published and Accepted Research Articles (clinical, basic science, other) in Refereed Journals:**

1. **Ofotokun I**, Carlson C, Gitlin SD, Elta G, Singleton TP, Markovitz DM. Acute cytomegalovirus infection complicated by vascular thrombosis: a case report. *Clin Infect Dis*. 2001 Mar 15;32(6):983-6. doi: 10.1086/319353. Epub 2001 Mar 9. PMID: 11247723.
2. Ree T, Jennings PR, **Ofotokun I**. Chronic mucocutaneous candidiasis. *JAAPA*. 2002 Apr;15(4):67-70. PMID: 12012589.
3. Grim SA, Smith KM, Romanelli F, **Ofotokun I**. Treatment of azole-resistant oropharyngeal candidiasis with topical amphotericin B. *Ann Pharmacother*. 2002 Sep;36(9):1383-6. doi: 10.1345/aph.1C052. PMID: 12196056.
4. Grim SA, Romanelli F, Jennings PR, **Ofotokun I**. Late-onset drug fever associated with minocycline: case report and review of the literature. *Pharmacotherapy*. 2003 Dec;23(12):1659-62. doi: 10.1592/phco.23.12.1659.31966. PMID: 14695046.
5. **Ofotokun I**, Busch K, Lee Y, Hoven A. Pulmonary mycobacterium avium complex following immune-reconstitution after HAART therapy. *Infect Dis Clin Pract*. 2004;12:1-3.
6. Martin C, **Ofotokun I**, Rapp R, Empey K, Armitstead J, Pomeroy C, Hoven A, Evans M. Results of an antimicrobial control program at a university hospital. *Am J Health Syst Pharm*. 2005 Apr 1;62(7):732-8. doi: 10.1093/ajhp/62.7.732. PMID: 15790801.
7. **Ofotokun I**, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. *J Clin Pharmacol*. 2007 Aug;47(8):970-7. doi: 10.1177/0091270007302564. Epub 2007 Jul 5. PMID: 17615254; PMCID: PMC3073482.

8. **Ofotokun I**, Smithson SE, Lu C, Easley KA, Lennox JL. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. *Am J Med Sci.* 2007 Nov;334(5):334-41. doi: 10.1097/MAJ.0b013e31811ec780. PMID: 18004087; PMCID: PMC3075308.
9. **Ofotokun I**, Acosta EP, Lennox JL, Pan Y, Easley KA. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. *Pharmacotherapy.* 2008 Jan;28(1):74-81. doi: 10.1592/phco.28.1.74. PMID: 18154477; PMCID: PMC3073489.
10. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Laloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med.* 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609. PMID: 18480202; PMCID: PMC3885902.
11. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. *AIDS.* 2009 Jun 1;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377. PMID: 19417580; PMCID: PMC2739977.
12. **Ofotokun I**, Chuck SK, Schmotzer B, O'Neil KL. Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients. *AIDS Res Ther.* 2009 Dec 22;6:29. doi: 10.1186/1742-6405-6-29. PMID: 20028544; PMCID: PMC2809072.
13. **Ofotokun I**, Binongo JN, Rosenberg ES, Kane M, Ifland R, Lennox JL, Easley KA. Culturally-adapted and audio-technology assisted HIV/AIDS awareness and education program in rural Nigeria: a cohort study. *BMC Int Health Hum Rights.* 2010 Feb 2;10:2. doi: 10.1186/1472-698X-10-2. PMID: 20181073; PMCID: PMC2834647.
14. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, **Ofotokun I**, Weitzmann MN. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. *Proc Natl Acad Sci U S A.* 2010 Aug 3;107(31):13848-53. doi: 10.1073/pnas.1003020107. Epub 2010 Jul 19. PMID: 20643942; PMCID: PMC2922243.
15. McComsey GA, Walker UA, Budhathoki CB, Su Z, Currier JS, Kosmiski L, Naini LG, Charles S, Medvik K, Aberg JA; AIDS Clinical Trials Group A5229 Team. Uridine supplementation in the treatment of HIV lipodystrophy: results of ACTG 5229. *AIDS.* 2010 Oct 23;24(16):2507-15. doi: 10.1097/QAD.0b013e32833ea9bc. PMID: 20827170; PMCID: PMC2956768.
16. Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW; AIDS Clinical Trials Group Study A5142 Protocol Team. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. *J Acquir Immune Defic Syndr.* 2011 Apr;56(4):344-8. doi: 10.1097/QAI.0b013e31820cf029. PMID: 21350368; PMCID: PMC3086845.
17. Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaud HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A; Workshop Pharmacogenomics-A Path Towards Personalized HIV Care. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. *HIV Clin Trials.* 2011 Sep-Oct;12(5):277-85. doi: 10.1310/hct1205-277. PMID: 22180526; PMCID: PMC3322423.
18. **Ofotokun I**, Lennox JL, Eaton ME, Ritchie JC, Easley KA, Masalovich SE, Long MC, Acosta EP. Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. *J Clin Pharmacol.* 2011 Nov;51(11):1539-48. doi: 10.1177/0091270010385118. Epub 2011 Jan 5. PMID: 21209245; PMCID: PMC3128238.

19. Holstad MM, Baumann M, **Ofotokun I**, Logwood SJ. Focus Group Evaluation of the LIVE Network-An Audio Music Program to Promote ART Adherence Self-Management. *Music Med*. 2012 Apr 1;4(2):74-81. doi: 10.1177/1943862111433875. PMID: 24013689; PMCID: PMC3765028.
20. **Ofotokun I**, Sheth AN, Sanford SE, Easley KA, Shenvi N, White K, Eaton ME, Del Rio C, Lennox JL. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. *AIDS Res Hum Retroviruses*. 2012 Oct;28(10):1196-206. doi: 10.1089/AID.2011.0336. Epub 2012 Apr 20. PMID: 22364141; PMCID: PMC3448110.
21. Acosta EP, Limoli KL, Trinh L, Parkin NT, King JR, Weidler JM, **Ofotokun I**, Petropoulos CJ. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. *Antimicrob Agents Chemother*. 2012 Nov;56(11):5938-45. doi: 10.1128/AAC.00691-12. Epub 2012 Sep 10. PMID: 22964257; PMCID: PMC3486606.
22. James AM, King JR, **Ofotokun I**, Sheth AN, Acosta EP. Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives. *J Exp Pharmacol*. 2013 Aug 1;5:55-64. doi: 10.2147/JEP.S45308. PMID: 27186136; PMCID: PMC4863541.
23. Holstad MM, **Ofotokun I**, Higgins M, Logwood S. The LIVE Network: a music-based messaging program to promote ART adherence self-management. *AIDS Behav*. 2013 Nov;17(9):2954-62. doi: 10.1007/s10461-013-0581-2. PMID: 23934269; PMCID: PMC3889150.
24. Zaeh S, Kempker R, Stenehjem E, Blumberg HM, Temesgen O, **Ofotokun I**, Tenna A. Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. *Int J Tuberc Lung Dis*. 2013 Nov;17(11):1396-401. doi: 10.5588/ijtld.13.0315. PMID: 24125440; PMCID: PMC3992289.
25. Wang K, D'Argenio DZ, Acosta EP, Sheth AN, Delille C, Lennox JL, Kerstner-Wood C, **Ofotokun I**. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients. *Clin Pharmacokinet*. 2014 Apr;53(4):361-71. doi: 10.1007/s40262-013-0122-1. PMID: 24311282; PMCID: PMC3962720.
26. Sheth AN, Evans-Strickfaden T, Haaland R, Martin A, Gatcliffe C, Adesoye A, Omondi MW, Lupo LD, Danavall D, Easley K, Chen CY, Pau CP, Hart C, **Ofotokun I**. HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle. *J Infect Dis*. 2014 Sep 1;210(5):736-44. doi: 10.1093/infdis/jiu166. Epub 2014 Mar 18. PMID: 24643223; PMCID: PMC4202306.
27. Delille CA, Pruett ST, Marconi VC, Lennox JL, Armstrong WS, Arrendale RF, Sheth AN, Easley KA, Acosta EP, Vunnava A, **Ofotokun I**. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. *J Clin Pharmacol*. 2014 Sep;54(9):1063-71. doi: 10.1002/jcph.298. Epub 2014 Apr 8. PMID: 24691856; PMCID: PMC4396178.
28. Lennox JL, Landovitz RJ, Ribaldo HJ, **Ofotokun I**, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: a randomized, controlled equivalence trial. *Ann Intern Med*. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: *Ann Intern Med*. 2014 Nov 4;161(9):680. PMID: 25285539; PMCID: PMC4412467.
29. Lennox JL, Landovitz RJ, Ribaldo HJ, **Ofotokun I**, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG

- A5257 Team. Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. *Ann Intern Med.* 2014 Oct 7;161(7):I-22. doi: 10.7326/P14-9035. PMID: 25285557.
30. Titanji K, Vunnava A, Sheth AN, Delille C, Lennox JL, Sanford SE, Foster A, Knezevic A, Easley KA, Weitzmann MN, **Ofotokun I**. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. *PLoS Pathog.* 2014 Nov 13;10(10):e1004497. doi: 10.1371/journal.ppat.1004497. PMID: 25393853; PMCID: PMC4231117.
  31. Haddad LB, Polis CB, Sheth AN, Brown J, Kourtis AP, King C, Chakraborty R, **Ofotokun I**. Contraceptive methods and risk of HIV acquisition or female-to-male transmission. *Curr HIV/AIDS Rep.* 2014 Dec;11(4):447-58. doi: 10.1007/s11904-014-0236-6. PMID: 25297973; PMCID: PMC4310558.
  32. Lahiri CD, Tao S, Jiang Y, Sheth AN, Acosta EP, Marconi VC, Armstrong WS, Schinazi RF, Vunnava A, Sanford S, **Ofotokun I**. Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients. *AIDS.* 2015 Jun 1;29(9):1113-5. doi: 10.1097/QAD.0000000000000659. PMID: 25870991; PMCID: PMC4490037.
  33. **Ofotokun I**, Na LH, Landovitz RJ, Ribaldo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. *Clin Infect Dis.* 2015 Jun 15;60(12):1842-51. doi: 10.1093/cid/civ193. Epub 2015 Mar 12. PMID: 25767256; PMCID: PMC4660025.
  34. Vardhanabhuti S, Ribaldo HJ, Landovitz RJ, **Ofotokun I**, Lennox JL, Currier JS, Olson LM, Haas DW. Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. *Open Forum Infect Dis.* 2015 Jul 1;2(3):ofv085. doi: 10.1093/ofid/ofv085. PMID: 26180834; PMCID: PMC4498287.
  35. **Ofotokun I**, Titanji K, Vikulina T, Roser-Page S, Yamaguchi M, Zayzafoon M, Williams IR, Weitzmann MN. Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. *Nat Commun.* 2015 Sep 22;6:8282. doi: 10.1038/ncomms9282. PMID: 26392000; PMCID: PMC4580984.
  36. Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaldo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, **Ofotokun I**, Brown T; AIDS Clinical Trials Group A5303 Study Team. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. *Clin Infect Dis.* 2015 Oct 1;61(7):1179-88. doi: 10.1093/cid/civ455. Epub 2015 Jun 9. PMID: 26060295; PMCID: PMC4560904.
  37. Lahiri CD, Dugan KB, Xie X, Reimers L, Burk RD, Anastos K, Massad LS, Eltoun IE, Xue X, D'Souza G, Flowers L, Palefsky JM, Rahangdale L, Strickler HD, **Ofotokun I**. Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women. *J Acquir Immune Defic Syndr.* 2015 Oct 1;70(2):e63-6. doi: 10.1097/QAI.0000000000000752. PMID: 26181819; PMCID: PMC4573346.
  38. Sheth AN, **Ofotokun I**, Buchacz K, Armon C, Chmiel JS, Hart RL, Baker R, Brooks JT, Palella FJ Jr. Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996-2011. *J Acquir Immune Defic Syndr.* 2016 Jan 1;71(1):47-56. doi: 10.1097/QAI.0000000000000813. PMID: 26334737; PMCID: PMC4713274.
  39. Haddad LB, Machen LK, Cordes S, Huylebroeck B, Delaney A, **Ofotokun I**, Nguyen ML, Jamieson DJ. Future desire for children among women living with HIV in Atlanta, Georgia. *AIDS Care.* 2016;28(4):455-9. doi: 10.1080/09540121.2015.1114996. Epub 2015 Dec 24. PMID: 26702869.

40. **Ofotokun I**, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F, Rogers K, Sheth AN, Lahiri CD, Lennox JL, Weitzmann MN. Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. *AIDS*. 2016 Jan 28;30(3):405-14. doi: 10.1097/QAD.0000000000000918. PMID: 26760232; PMCID: PMC4712729.
41. Lahiri CD, Reed-Walker K, Sheth AN, Acosta EP, Vunnava A, **Ofotokun I**. Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens. *J Clin Pharmacol*. 2016 Apr;56(4):492-6. doi: 10.1002/jcph.612. Epub 2015 Oct 20. PMID: 26247878; PMCID: PMC4744587.
42. Chan ES, Landay AL, Brown TT, Ribaldo HJ, Mirmonsef P, **Ofotokun I**, Weitzmann MN, Martinson J, Klingman KL, Eron JJ, Fichtenbaum CJ, Plants J, Taiwo BO. Differential CD4+ cell count increase and CD4+: CD8+ ratio normalization with maraviroc compared with tenofovir. *AIDS*. 2016 Aug 24;30(13):2091-7. doi: 10.1097/QAD.0000000000001181. PMID: 27281061; PMCID: PMC4966543.
43. **Ofotokun I**, Titanji K, Lahiri CD, Vunnava A, Foster A, Sanford SE, Sheth AN, Lennox JL, Knezevic A, Ward L, Easley KA, Powers P, Weitzmann MN. A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial. *Clin Infect Dis*. 2016 Sep 1;63(5):663-671. doi: 10.1093/cid/ciw331. Epub 2016 May 18. PMID: 27193748; PMCID: PMC4981757.
44. Landovitz RJ, Tran TT, Cohn SE, **Ofotokun I**, Godfrey C, Kuritzkes DR, Lennox JL, Currier JS, Ribaldo HJ. HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. *AIDS Behav*. 2016 Dec;20(12):2983-2995. doi: 10.1007/s10461-016-1365-2. PMID: 26979419; PMCID: PMC5026544.
45. Haddad LB, Wall KM, Mehta CC, Golub ET, Rahangdale L, Kempf MC, Karim R, Wright R, Minkoff H, Cohen M, Kassaye S, Cohan D, **Ofotokun I**, Cohn SE. Trends of and factors associated with live-birth and abortion rates among HIV-positive and HIV-negative women. *Am J Obstet Gynecol*. 2017 Jan;216(1):71.e1-71.e16. doi: 10.1016/j.ajog.2016.09.079. Epub 2016 Sep 15. PMID: 27640942; PMCID: PMC5182149.
46. Bhagwat P, **Ofotokun I**, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS. Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes. *Antivir Ther*. 2017;22(7):577-586. doi: 10.3851/IMP3148. Epub 2017 Mar 1. PMID: 28248190; PMCID: PMC5610106.
47. Hanna DB, Lin J, Post WS, Hodis HN, Xue X, Anastos K, Cohen MH, Gange SJ, Haberlen SA, Heath SL, Lazar JM, Liu C, Mack WJ, **Ofotokun I**, Palella FJ, Tien PC, Witt MD, Landay AL, Kingsley LA, Tracy RP, Kaplan RC. Association of Macrophage Inflammation Biomarkers With Progression of Subclinical Carotid Artery Atherosclerosis in HIV-Infected Women and Men. *J Infect Dis*. 2017 May 1;215(9):1352-1361. doi: 10.1093/infdis/jix082. PMID: 28199691; PMCID: PMC5722037.
48. Enkhmaa B, Anuurad E, Zhang W, Li CS, Kaplan R, Lazar J, Merenstein D, Karim R, Aouizerat B, Cohen M, Butler K, Pahwa S, **Ofotokun I**, Adimora AA, Golub E, Berglund L. Lipoprotein(a) and HIV: Allele-Specific Apolipoprotein(a) Levels Predict Carotid Intima-Media Thickness in HIV-Infected Young Women in the Women's Interagency HIV Study. *Arterioscler Thromb Vasc Biol*. 2017 May;37(5):997-1004. doi: 10.1161/ATVBAHA.117.309137. Epub 2017 Mar 23. PMID: 28336560; PMCID: PMC5408307.
49. Iyer SS, Sabula MJ, Mehta CC, Haddad LB, Brown NL, Amara RR, **Ofotokun I**, Sheth AN. Characteristics of HIV target CD4 T cells collected using different sampling methods from the genital tract of HIV seronegative women. *PLoS One*. 2017 Jun 1;12(6):e0178193. doi: 10.1371/journal.pone.0178193. PMID: 28570576; PMCID: PMC5453484.

50. Rubin LH, Maki PM, Springer G, Benning L, Anastos K, Gustafson D, Villacres MC, Jiang X, Adimora AA, Waldrop-Valverde D, Vance DE, Bolivar H, Alden C, Martin EM, Valcour VG; Women's Interagency HIV Study. Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression. *Neurology*. 2017 Oct 10;89(15):1594-1603. doi: 10.1212/WNL.0000000000004491. Epub 2017 Sep 13. PMID: 28904086; PMCID: PMC5634661.
51. Sarkar M, Dodge JL, Greenblatt RM, Kuniholm MH, DeHovitz J, Plankey M, Kovacs A, French AL, Seaberg EC, **Ofotokun I**, Fischl M, Overton E, Kelly E, Bacchetti P, Peters MG; Women's Interagency HIV Study. Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. *Clin Infect Dis*. 2017 Oct 30;65(10):1695-1702. doi: 10.1093/cid/cix643. PMID: 29020239; PMCID: PMC5850524.
52. Donahue Carlson R, Sheth AN, Read TD, Frisch MB, Mehta CC, Martin A, Haaland RE, Patel AS, Pau CP, Kraft CS, **Ofotokun I**. The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy. *J Infect Dis*. 2017 Nov 15;216(8):990-999. doi: 10.1093/infdis/jix420. PMID: 29029138; PMCID: PMC5853913.
53. Weitzmann MN, Vikulina T, Roser-Page S, Yamaguchi M, **Ofotokun I**. Homeostatic Expansion of CD4+ T Cells Promotes Cortical and Trabecular Bone Loss, Whereas CD8+ T Cells Induce Trabecular Bone Loss Only. *J Infect Dis*. 2017 Nov 27;216(9):1070-1079. doi: 10.1093/infdis/jix444. PMID: 28968828; PMCID: PMC5853557.
54. Lesko CR, Todd JV, Cole SR, Edmonds A, Pence BW, Edwards JK, Mack WJ, Bacchetti P, Rubtsova A, Gange SJ, Adimora AA; WIHS Investigators. Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. *Ann Epidemiol*. 2017 Dec;27(12):783-789.e2. doi: 10.1016/j.annepidem.2017.08.021. Epub 2017 Sep 5. PMID: 28939001; PMCID: PMC5714697.
55. Turan B, Rogers AJ, Rice WS, Atkins GC, Cohen MH, Wilson TE, Adimora AA, Merenstein D, Adedimeji A, Wentz EL, **Ofotokun I**, Metsch L, Tien PC, Johnson MO, Turan JM, Weiser SD. Association between Perceived Discrimination in Healthcare Settings and HIV Medication Adherence: Mediating Psychosocial Mechanisms. *AIDS Behav*. 2017 Dec;21(12):3431-3439. doi: 10.1007/s10461-017-1957-5. PMID: 29081045; PMCID: PMC5705383.
56. Shendre A, Wiener HW, Irvin MR, Aouizerat BE, Overton ET, Lazar J, Liu C, Hodis HN, Limdi NA, Weber KM, Gange SJ, Zhi D, Floris-Moore MA, **Ofotokun I**, Qi Q, Hanna DB, Kaplan RC, Shrestha S. Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS). *PLoS One*. 2017 Dec 4;12(12):e0188725. doi: 10.1371/journal.pone.0188725. PMID: 29206233; PMCID: PMC5714351.
57. Comeau DL, Alvarez JA, Bhatti P, Paulsen DF, Quarshie A, Escoffery C, **Ofotokun I**, Eisen H, Ziegler TR, Blumberg HM. Building Diverse Careers in Clinical and Translational Research: Evaluation of a Certificate Program in Translational Research. *J Clin Transl Sci*. 2018 Feb;2(1):38-47. doi: 10.1017/cts.2018.19. Epub 2018 Jul 6. PMID: 30881696; PMCID: PMC6419973.
58. Adimora AA, Ramirez C, Benning L, Greenblatt RM, Kempf MC, Tien PC, Kassaye SG, Anastos K, Cohen M, Minkoff H, Wingood G, **Ofotokun I**, Fischl MA, Gange S. Cohort Profile: The Women's Interagency HIV Study (WIHS). *Int J Epidemiol*. 2018 Apr 1;47(2):393-394i. doi: 10.1093/ije/dyy021. PMID: 29688497; PMCID: PMC5913596.
59. Titanji K, Vunnava A, Foster A, Sheth AN, Lennox JL, Knezevic A, Shenvi N, Easley KA, **Ofotokun I**, Weitzmann MN. T-cell receptor activator of nuclear factor- $\kappa$ B ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts. *AIDS*. 2018 Apr 24;32(7):885-894. doi: 10.1097/QAD.0000000000001764. PMID: 29424771; PMCID: PMC5869175.

60. Moran CA, Sheth AN, Mehta CC, Hanna DB, Gustafson DR, Plankey MW, Mack WJ, Tien PC, French AL, Golub ET, Quyyumi A, Kaplan RC, **Ofotokun I**. The association of C-reactive protein with subclinical cardiovascular disease in HIV-infected and HIV-uninfected women. *AIDS*. 2018 May 15;32(8):999-1006. doi: 10.1097/QAD.0000000000001785. PMID: 29438198; PMCID: PMC5920777.
61. Colasanti J, Galaviz KI, Christina Mehta C, Palar K, Schneider MF, Tien P, Adimora AA, Alcaide M, Cohen MH, Gustafson D, Karim R, Merenstein D, Sharma A, Wingood G, Marconi VC, **Ofotokun I**, Ali MK. Room for Improvement: The HIV-Diabetes Care Continuum Over 15 Years in the Women's Interagency HIV Study. *Open Forum Infect Dis*. 2018 May 22;5(6):ofy121. doi: 10.1093/ofid/ofy121. PMID: 29942823; PMCID: PMC6007350.
62. Lahiri CD, Brown NL, Ryan KJ, Acosta EP, Sheth AN, Mehta CC, Ingersoll J, **Ofotokun I**. HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy. *AIDS*. 2018 Sep 24;32(15):2151-2159. doi: 10.1097/QAD.0000000000001945. PMID: 30005011; PMCID: PMC6200454.
63. Bekhbat M, Mehta CC, Kelly SD, Vester A, **Ofotokun I**, Felger J, Wingood G, Anastos K, Gustafson DR, Kassaye S, Milam J, Aouizerat B, Weber K, Golub ET, Moore MF, Diclemente R, Fischl M, Kempf MC, Maki P, Neigh GN. HIV and symptoms of depression are independently associated with impaired glucocorticoid signaling. *Psychoneuroendocrinology*. 2018 Oct;96:118-125. doi: 10.1016/j.psyneuen.2018.06.013. Epub 2018 Jun 18. PMID: 29936334; PMCID: PMC6131054.
64. Enkhmaa B, Anuurad E, Zhang W, Li CS, Kaplan R, Lazar J, Merenstein D, Karim R, Aouizerat B, Cohen M, Butler K, Pahwa S, **Ofotokun I**, Adimora AA, Golub E, Berglund L. Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women's Interagency HIV Study. *J Lipid Res*. 2018 Oct;59(10):1967-1976. doi: 10.1194/jlr.P084517. Epub 2018 Jul 16. PMID: 30012717; PMCID: PMC6168315.
65. Bhagwat P, **Ofotokun I**, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS. Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race. *Open Forum Infect Dis*. 2018 Nov 16;5(11):ofy201. doi: 10.1093/ofid/ofy201. PMID: 30465010; PMCID: PMC6239079.
66. Galaviz KI, Schneider MF, Tien PC, Mehta CC, **Ofotokun I**, Colasanti J, Marconi VC, Palar K, Wingood G, Adimora AA, Alcaide M, Cohen MH, Gustafson D, Karim R, Konkle-Parker D, Merenstein D, Sharma A, Ali MK. Predicting diabetes risk among HIV-positive and HIV-negative women. *AIDS*. 2018 Nov 28;32(18):2767-2775. doi: 10.1097/QAD.0000000000002017. PMID: 30289812; PMCID: PMC6673643.
67. Palar K, Frongillo EA, Escobar J, Sheira LA, Wilson TE, Adedimeji A, Merenstein D, Cohen MH, Wentz EL, Adimora AA, **Ofotokun I**, Metsch L, Tien PC, Turan JM, Weiser SD. Food Insecurity, Internalized Stigma, and Depressive Symptoms Among Women Living with HIV in the United States. *AIDS Behav*. 2018 Dec;22(12):3869-3878. doi: 10.1007/s10461-018-2164-8. PMID: 29948333; PMCID: PMC6209540.
68. Tote KM, Raziano VT, Wall KM, Cordes S, **Ofotokun I**, Haddad LB. Contraceptive method use among HIV-positive women in a US urban outpatient clinic: an exploratory cross-sectional study. *Contraception*. 2018 Dec;98(6):492-497. doi: 10.1016/j.contraception.2018.07.140. Epub 2018 Aug 1. PMID: 30075117.
69. Whittle HJ, Sheira LA, Frongillo EA, Palar K, Cohen J, Merenstein D, Wilson TE, Adedimeji A, Cohen MH, Adimora AA, **Ofotokun I**, Metsch L, Turan JM, Wentz EL, Tien PC, Weiser SD. Longitudinal associations between food insecurity and substance use in a cohort of women with or at risk for HIV in the United States. *Addiction*. 2019 Jan;114(1):127-136. doi: 10.1111/add.14418. Epub 2018 Sep 25. PMID: 30109752; PMCID: PMC6516859.



70. Leddy AM, Roque A, Sheira LA, Frongillo EA, Landay AL, Adedimeji AA, Wilson TE, Merenstein D, Wentz E, Adimora AA, **Ofotokun I**, Metsch LR, Cohen MH, Tien PC, Turan JM, Turan B, Weiser SD. Food Insecurity Is Associated With Inflammation Among Women Living With HIV. *J Infect Dis*. 2019 Jan 9;219(3):429-436. doi: 10.1093/infdis/jiy511. PMID: 30165648; PMCID: PMC6325349.
71. Tuthill EL, Sheira LA, Palar K, Frongillo EA, Wilson TE, Adedimeji A, Merenstein D, Cohen MH, Wentz EL, Adimora AA, **Ofotokun I**, Metsch L, Kushel M, Turan JM, Konkle-Parker D, Tien PC, Weiser SD. Persistent Food Insecurity Is Associated with Adverse Mental Health among Women Living with or at Risk of HIV in the United States. *J Nutr*. 2019 Feb 1;149(2):240-248. doi: 10.1093/jn/nxy203. PMID: 30753638; PMCID: PMC6698636.
72. Conroy AA, Cohen MH, Frongillo EA, Tsai AC, Wilson TE, Wentz EL, Adimora AA, Merenstein D, **Ofotokun I**, Metsch L, Kempf MC, Adedimeji A, Turan JM, Tien PC, Weiser SD. Food insecurity and violence in a prospective cohort of women at risk for or living with HIV in the U.S. *PLoS One*. 2019 Mar 6;14(3):e0213365. doi: 10.1371/journal.pone.0213365. PMID: 30840700; PMCID: PMC6402690.
73. Patel AS, Goparaju L, Sales JM, Mehta CC, Blackstock OJ, Seidman D, **Ofotokun I**, Kempf MC, Fischl MA, Golub ET, Adimora AA, French AL, DeHovitz J, Wingood G, Kassaye S, Sheth AN. Brief Report: PrEP Eligibility Among At-Risk Women in the Southern United States: Associated Factors, Awareness, and Acceptability. *J Acquir Immune Defic Syndr*. 2019 Apr 15;80(5):527-532. doi: 10.1097/QAI.0000000000001950. PMID: 30649036; PMCID: PMC6519058.
74. Mueller KAL, Hanna DB, Ehinger E, Xue X, Baas L, Gawaz MP, Geisler T, Anastos K, Cohen MH, Gange SJ, Heath SL, Lazar JM, Liu C, Mack WJ, **Ofotokun I**, Tien PC, Hodis HN, Landay AL, Kaplan RC, Ley K. Loss of CXCR4 on non-classical monocytes in participants of the Women's Interagency HIV Study (WIHS) with subclinical atherosclerosis. *Cardiovasc Res*. 2019 May 1;115(6):1029-1040. doi: 10.1093/cvr/cvy292. PMID: 30520941; PMCID: PMC6735712.
75. Swaims-Kohlmeier A, Haddad LB, Li ZT, Brookmeyer KA, Baker JM, Widom CS, Lamousin JC, Chi KH, Chen CY, Kersh EN, Johnson JA, Herbst-Kralovetz MM, Hogben M, **Ofotokun I**, Kohlmeier JE. Chronic immune barrier dysregulation among women with a history of violence victimization. *JCI Insight*. 2019 May 16;4(10):e126097. doi: 10.1172/jci.insight.126097. PMID: 31092736; PMCID: PMC6542609.
76. Holstad MM, Higgins M, Bauman M, Farber EW, Waldrop-Valverde D, Okwandu O, **Ofotokun I**. Picture Pill Count: An Innovative, Reliable, Valid and Feasible Method to Measure Adherence to ART. *AIDS Behav*. 2019 Aug;23(8):2210-2217. doi: 10.1007/s10461-019-02513-9. PMID: 31041625.
77. Whittle HJ, Sheira LA, Wolfe WR, Frongillo EA, Palar K, Merenstein D, Wilson TE, Adedimeji A, Weber KM, Adimora AA, **Ofotokun I**, Metsch L, Turan JM, Wentz EL, Tien PC, Weiser SD. Food insecurity is associated with anxiety, stress, and symptoms of posttraumatic stress disorder in a cohort of women with or at risk of HIV in the United States. *J Nutr*. 2019 Aug 1;149(8):1393-1403. doi: 10.1093/jn/nxz093. PMID: 31127819; PMCID: PMC6675617.
78. Tamraz B, Reisner L, French AL, King ST, Fischl MA, **Ofotokun I**, Kashuba A, Milam J, Murphy K, Augenbraun M, Liu C, Finley PR, Aouizerat B, Cocohoba J, Gange S, Bacchetti P, Greenblatt RM. Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval-Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection. *Pharmacotherapy*. 2019 Sep;39(9):899-911. doi: 10.1002/phar.2312. Epub 2019 Aug 13. PMID: 31332819; PMCID: PMC7000174.
79. Wall KM, Haddad LB, Mehta CC, Golub ET, Rahangdale L, Dionne-Odom J, Karim R, Wright RL, Minkoff H, Cohen M, Kassaye SG, Cohan D, **Ofotokun I**, Cohn SE. Miscarriage among women in the United States Women's Interagency HIV Study, 1994-2017. *Am J Obstet Gynecol*. 2019

Oct;221(4):347.e1-347.e13. doi: 10.1016/j.ajog.2019.05.034. Epub 2019 May 25. PMID: 31136732; PMCID: PMC6878114.

80. Cedarbaum E, Ma Y, Scherzer R, Price JC, Adimora AA, Bamman M, Cohen M, Fischl MA, Matsushita K, **Ofotokun I**, Plankey M, Seaberg EC, Yin MT, Grunfeld C, Vartanian S, Sharma A, Tien PC. Contributions of HIV, hepatitis C virus, and traditional vascular risk factors to peripheral artery disease in women. *AIDS*. 2019 Nov 1;33(13):2025-2033. doi: 10.1097/QAD.0000000000002319. PMID: 31335806; PMCID: PMC6774831.
81. Rubtsova AA, Wingood GM, **Ofotokun I**, Gustafson D, Vance DE, Sharma A, Adimora AA, Holstad M. Prevalence and Correlates of Self-Rated Successful Aging Among Older Women Living With HIV. *J Acquir Immune Defic Syndr*. 2019 Dec 1;82 Suppl 2(2):S162-S169. doi: 10.1097/QAI.0000000000002175. PMID: 31658205; PMCID: PMC6830959.
82. Gursahaney PR, Cordes S, **Ofotokun I**, Wall KM, Jamieson DJ, Haddad LB. Factors associated with condom use among HIV-positive women living in Atlanta, Georgia. *PLoS One*. 2019 Dec 13;14(12):e0225406. doi: 10.1371/journal.pone.0225406. PMID: 31834885; PMCID: PMC6910822.
83. Moran CA, Southmayd G, Devireddy CM, Quyyumi AA, **Ofotokun I**, Liberman HA, Jaber W, Sheth AN. Clinical and procedural characteristics of persons living with HIV presenting with acute coronary syndrome. *AIDS*. 2020 Jan 1;34(1):81-90. doi: 10.1097/QAD.0000000000002393. PMID: 31634195; PMCID: PMC7002021.
84. Whittle HJ, Leddy AM, Shieh J, Tien PC, **Ofotokun I**, Adimora AA, Turan JM, Frongillo EA, Turan B, Weiser SD. Precarity and health: Theorizing the intersection of multiple material-need insecurities, stigma, and illness among women in the United States. *Soc Sci Med*. 2020 Jan;245:112683. doi: 10.1016/j.socscimed.2019.112683. Epub 2019 Nov 16. PMID: 31760320; PMCID: PMC7111434.
85. Halpin SN, Ge L, Mehta CC, Gustafson D, Robertson KR, Rubin LH, Sharma A, Vance D, Valcour V, Waldrop-Valverde D, **Ofotokun I**. Psychosocial Resources and Emotions in Women Living With HIV Who Have Cognitive Impairment: Applying the Socio-Emotional Adaptation Theory. *Res Theory Nurs Pract*. 2020 Jan 1;34(1):49-64. doi: 10.1891/1541-6577.34.1.49. PMID: 31937636; PMCID: PMC8062986.
86. Lahiri CD, Nguyen ML, Mehta CC, Mosunjac M, Tadros T, Unger ER, Rajeevan MS, Richards J, **Ofotokun I**, Flowers L. Pilot Study of Markers for High-grade Anal Dysplasia in a Southern Cohort From the Women's Interagency Human Immunodeficiency Virus Study. *Clin Infect Dis*. 2020 Mar 3;70(6):1121-1128. doi: 10.1093/cid/ciz336. PMID: 31058984; PMCID: PMC7319055.
87. Haddad LB, Swaims-Kohlmeier A, Mehta CC, Haaland RE, Brown NL, Sheth AN, Chien H, Titanji K, Achilles SL, Lupo D, Hart CE, **Ofotokun I**. Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood. *PLoS One*. 2020 Mar 26;15(3):e0230473. doi: 10.1371/journal.pone.0230473. PMID: 32214321; PMCID: PMC7098611.
88. Cope AB, Edmonds A, Ludema C, Cole SR, Eron JJ, Anastos K, Cocohoba J, Cohen M, **Ofotokun I**, Golub ET, Kassaye S, Konkle-Parker D, Metsch LR, Wilson TE, Adimora AA. Neighborhood Poverty and Control of HIV, Hypertension, and Diabetes in the Women's Interagency HIV Study. *AIDS Behav*. 2020 Jul;24(7):2033-2044. doi: 10.1007/s10461-019-02757-5. PMID: 31907676; PMCID: PMC7319872.
89. Rice WS, Fletcher FE, Akingbade B, Kan M, Whitfield S, Ross S, Gakumo CA, **Ofotokun I**, Konkle-Parker DJ, Cohen MH, Wingood GM, Pence BW, Adimora AA, Taylor TN, Wilson TE, Weiser SD, Kempf MC, Turan B, Turan JM. Quality of care for Black and Latina women living with HIV in the U.S.: a qualitative study. *Int J Equity Health*. 2020 Jul 6;19(1):115. doi: 10.1186/s12939-020-01230-3. PMID: 32631424; PMCID: PMC7336413.

90. Kerchberger AM, Sheth AN, Angert CD, Mehta CC, Summers NA, **Ofotokun I**, Gustafson D, Weiser SD, Sharma A, Adimora AA, French AL, Augenbraun M, Cocohoba J, Kassaye S, Bolivar H, Govindarajulu U, Konkle-Parker D, Golub ET, Lahiri CD. Weight Gain Associated With Integrase Strand Transfer Inhibitor Use in Women. *Clin Infect Dis*. 2020 Jul 27;71(3):593-600. doi: 10.1093/cid/ciz853. PMID: 31504324; PMCID: PMC7384314.
91. Titanji K, **Ofotokun I**, Weitzmann MN. Immature/transitional B-cell expansion is associated with bone loss in HIV-infected individuals with severe CD4+ T-cell lymphopenia. *AIDS*. 2020 Aug 1;34(10):1475-1483. doi: 10.1097/QAD.0000000000002563. PMID: 32675561; PMCID: PMC7371241.
92. Dumond JB, Bay CP, Nelson JAE, Davalos A, Edmonds A, De Paris K, Sykes C, Anastos K, Sharma R, Kassaye S, Tamraz B, French AL, Gange S, **Ofotokun I**, Fischl MA, Vance DE, Adimora AA. Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine. *Antimicrob Agents Chemother*. 2020 Aug 20;64(9):e00177-20. doi: 10.1128/AAC.00177-20. PMID: 32631821; PMCID: PMC7449168.
93. Leddy AM, Sheira LA, Tamraz B, Sykes C, Kashuba ADM, Wilson TE, Adedimeji A, Merenstein D, Cohen MH, Wentz EL, Adimora AA, **Ofotokun I**, Metsch LR, Turan JM, Bacchetti P, Weiser SD. Food Insecurity Is Associated With Lower Levels of Antiretroviral Drug Concentrations in Hair Among a Cohort of Women Living With Human Immunodeficiency Virus in the United States. *Clin Infect Dis*. 2020 Sep 12;71(6):1517-1523. doi: 10.1093/cid/ciz1007. PMID: 31608363; PMCID: PMC7486839.
94. Collins LF, Moran CA, Oliver NT, Moanna A, Lahiri CD, Colasanti JA, Kelley CF, Nguyen ML, Marconi VC, Armstrong WS, **Ofotokun I**, Sheth AN. Clinical characteristics, comorbidities and outcomes among persons with HIV hospitalized with coronavirus disease 2019 in Atlanta, Georgia. *AIDS*. 2020 Oct 1;34(12):1789-1794. doi: 10.1097/QAD.0000000000002632. PMID: 32675581; PMCID: PMC7484356.
95. Weiser SD, Sheira LA, Palar K, Kushel M, Wilson TE, Adedimeji A, Merenstein D, Cohen M, Turan JM, Metsch L, Adimora AA, **Ofotokun I**, Wentz E, Tien PC, Frongillo EA. Mechanisms from Food Insecurity to Worse HIV Treatment Outcomes in US Women Living with HIV. *AIDS Patient Care STDS*. 2020 Oct;34(10):425-435. doi: 10.1089/apc.2020.0009. Epub 2020 Sep 17. PMID: 32941054; PMCID: PMC7585614.
96. **Ofotokun I**, Collins LF, Titanji K, Foster A, Moran CA, Sheth AN, Lahiri CD, Lennox JL, Ward L, Easley KA, Weitzmann MN. Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial. *Clin Infect Dis*. 2020 Oct 23;71(7):1655-1663. doi: 10.1093/cid/ciz1027. PMID: 31621838; PMCID: PMC7755092.
97. Summers NA, Lahiri CD, Angert CD, Aldredge A, Mehta CC, **Ofotokun I**, Kerchberger AM, Gustafson D, Weiser SD, Kassaye S, Konkle-Parker D, Sharma A, Adimora AA, Bolivar H, Cocohoba J, French AL, Golub ET, Sheth AN. Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virologically Controlled Women. *J Acquir Immune Defic Syndr*. 2020 Nov 1;85(3):355-362. doi: 10.1097/QAI.0000000000002447. PMID: 33060420; PMCID: PMC7577246.
98. Leddy AM, Whittle HJ, Shieh J, Ramirez C, **Ofotokun I**, Weiser SD. Exploring the role of social capital in managing food insecurity among older women in the United States. *Soc Sci Med*. 2020 Nov;265:113492. doi: 10.1016/j.socscimed.2020.113492. Epub 2020 Nov 2. PMID: 33162195; PMCID: PMC7757784.
99. Tan JY, A Sheira L, Frongillo EA, A Adimora A, Tien PC, Konkle-Parker D, Golub ET, Merenstein D, Levin S, Cohen M, **Ofotokun I**, A Fischl M, Rubin LH, Weiser SD. Food insecurity and neurocognitive function among women living with or at risk for HIV in the United States. *Am J Clin*

Nutr. 2020 Nov 11;112(5):1280-1286. doi: 10.1093/ajcn/nqaa209. PMID: 32844175; PMCID: PMC7657325.

100. Kamkwala AR, Wang K, O'Halloran J, Williams DW, Dastgheyb R, Fitzgerald KC, Spence AB, Maki PM, Gustafson DR, Milam J, Sharma A, Weber KM, Adimora AA, **Ofotokun I**, Sheth AN, Lahiri CD, Fischl MA, Konkle-Parker D, Xu Y, Rubin LH. Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV. *AIDS Behav.* 2021 Jan;25(1):225-236. doi: 10.1007/s10461-020-02967-2. PMID: 32638219; PMCID: PMC7948485.
101. Williams DW, Li Y, Dastgheyb R, Fitzgerald KC, Maki PM, Spence AB, Gustafson DR, Milam J, Sharma A, Adimora AA, **Ofotokun I**, Fischl MA, Konkle-Parker D, Weber KM, Xu Y, Rubin LH. Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV. *J Neuroimmune Pharmacol.* 2021 Mar;16(1):181-194. doi: 10.1007/s11481-019-09899-2. Epub 2020 Jan 13. PMID: 31933016; PMCID: PMC7430262.
102. Rubin LH, Li Y, Fitzgerald KC, Dastgheyb R, Spence AB, Maki PM, Sharma A, Gustafson DR, Milam J, Weber KM, Adimora AA, Haughey NJ, **Ofotokun I**, Fischl MA, Konkle-Parker D, Xu Y, Williams DW. Associations between Antiretrovirals and Cognitive Function in Women with HIV. *J Neuroimmune Pharmacol.* 2021 Mar;16(1):195-206. doi: 10.1007/s11481-020-09910-1. Epub 2020 Mar 24. PMID: 32212091; PMCID: PMC7511435.
103. Ehinger E, Ghosheh Y, Pramod AB, Lin J, Hanna DB, Mueller K, Durant CP, Baas L, Qi Q, Wang T, Buscher K, Anastos K, Lazar JM, Mack WJ, Tien PC, Cohen MH, **Ofotokun I**, Gange S, Heath SL, Hodis HN, Tracy RP, Landay AL, Kaplan RC, Ley K. Classical monocyte transcriptomes reveal significant anti-inflammatory statin effect in women with chronic HIV. *Cardiovasc Res.* 2021 Mar 21;117(4):1166-1177. doi: 10.1093/cvr/cvaa188. PMID: 32658258; PMCID: PMC7983000.
104. Epps F, Wiley Z, Teunis LJ, Johnson TM 2nd, Patzer RE, **Ofotokun I**, Franks N. A Framework for Mobilizing Health Care to Respond to the Community Within the COVID-19 Pandemic. *Prev Chronic Dis.* 2021 Apr 1;18:E30. doi: 10.5888/pcd18.200572. PMID: 33793392; PMCID: PMC8021142.
105. O'Halloran JA, Wang K, Spence AB, Williams DW, Dastgheyb R, Fitzgerald KC, Kamkwala AR, Maki PM, Sharma A, Gustafson DR, Milam J, Weber KM, Adimora AA, **Ofotokun I**, Fischl MA, Konkle-Parker D, Lahiri CD, Sheth AN, Xu Y, Rubin LH. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV. *J Acquir Immune Defic Syndr.* 2021 Apr 15;86(5):593-599. doi: 10.1097/QAI.0000000000002608. PMID: 33394812; PMCID: PMC8319920.
106. Collins LF, Sheth AN, Mehta CC, Naggie S, Golub ET, Anastos K, French AL, Kassaye S, Taylor T, Fischl MA, Adimora AA, Kempf MC, Palella FJ, Tien PC, **Ofotokun I**. The Prevalence and Burden of Non-AIDS Comorbidities Among Women Living With or at Risk for Human Immunodeficiency Virus Infection in the United States. *Clin Infect Dis.* 2021 Apr 26;72(8):1301-1311. doi: 10.1093/cid/ciaa204. PMID: 32115628; PMCID: PMC8075036.
107. Shieh JA, Leddy AM, Whittle HJ, **Ofotokun I**, Adimora AA, Tien PC, Weiser SD. Perceived Neighborhood-Level Drivers of Food Insecurity Among Aging Women in the United States: A Qualitative Study. *J Acad Nutr Diet.* 2021 May;121(5):844-853. doi: 10.1016/j.jand.2020.12.019. Epub 2021 Feb 3. PMID: 33547033; PMCID: PMC8084897.
108. Galaviz KI, Schneider MF, Tien PC, Althoff KN, Ali MK, **Ofotokun I**, Brown TT. Expanding the Finnish Diabetes Risk Score for Predicting Diabetes Incidence in People Living with HIV. *AIDS Res Hum Retroviruses.* 2021 May;37(5):373-379. doi: 10.1089/AID.2020.0247. Epub 2021 Apr 12. PMID: 33683149; PMCID: PMC8112710.
109. Strickler HD, Keller MJ, Hessol NA, Eltoun IE, Einstein MH, Castle PE, Massad LS, Flowers L, Rahangdale L, Atrio JM, Ramirez C, Minkoff H, Adimora AA, **Ofotokun I**, Colie C, Huchko MJ,

- Fischl M, Wright R, D'Souza G, Leider J, Diaz O, Sanchez-Keeland L, Shrestha S, Xie X, Xue X, Anastos K, Palefsky JM, Burk RD. Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus. *Clin Infect Dis*. 2021 May 4;72(9):1529-1537. doi: 10.1093/cid/ciaa1317. PMID: 32881999; PMCID: PMC8096228.
110. Leddy AM, Zakaras JM, Shieh J, Conroy AA, **Oforokun I**, Tien PC, Weiser SD. Intersections of food insecurity, violence, poor mental health and substance use among US women living with and at risk for HIV: Evidence of a syndemic in need of attention. *PLoS One*. 2021 May 26;16(5):e0252338. doi: 10.1371/journal.pone.0252338. PMID: 34038490; PMCID: PMC8153505.
  111. Lahiri CD, Xu Y, Wang K, Alvarez JA, Sheth AN, O'Halloran J, Spence AB, Tien P, Gustafson DR, Milam J, Fischl MA, Konkle-Parker D, Adimora AA, Sharma A, Weber KM, **Oforokun I**, Rubin LH. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV. *AIDS Res Hum Retroviruses*. 2021 Jun;37(6):461-467. doi: 10.1089/AID.2020.0197. Epub 2021 Jan 12. PMID: 33231474; PMCID: PMC8213005.
  112. Tan JY, Sheira LA, Frongillo EA, Gustafson D, Sharma A, Merenstein D, Cohen MH, Golub E, Edmonds A, **Oforokun I**, Fischl M, Konkle-Parker D, Neilands T, Tien P, Weiser SD. Food insecurity and frailty among women with and without HIV in the United States: a cross-sectional analysis. *J Int AIDS Soc*. 2021 Jun;24(6):e25751. doi: 10.1002/jia2.25751. PMID: 34128343; PMCID: PMC8204023.
  113. Peters BA, Xue X, Sheira LA, Qi Q, Sharma A, Santoro N, Alcaide ML, **Oforokun I**, Adimora AA, McKay HS, Tien PC, Michel KG, Gustafson D, Turan B, Landay AL, Kaplan RC, Weiser SD. Menopause is associated with immune activation in women with HIV. *J Infect Dis*. 2021 Jun 26:jiab341. doi: 10.1093/infdis/jiab341. Epub ahead of print. PMID: 34174074.
  114. Collins LF, Shantha JG, Nesper PL, Sheth AN, Fawzi AA, Yeh S, **Oforokun I**. Assessment of retinal microvascular health by optical coherence tomography angiography among persons with HIV. *AIDS*. 2021 Jul 1;35(8):1321-1324. doi: 10.1097/QAD.0000000000002890. PMID: 33756509; PMCID: PMC8172530.
  115. Curtis KA, Rudolph DL, Pan Y, Delaney K, Anastos K, DeHovitz J, Kassaye SG, Hanson CV, French AL, Golub E, Adimora AA, **Oforokun I**, Bolivar H, Kempf MC, Peters PJ, Switzer WM. Evaluation of the Abbott ARCHITECT HIV Ag/Ab combo assay for determining recent HIV-1 infection. *PLoS One*. 2021 Jul 1;16(7):e0242641. doi: 10.1371/journal.pone.0242641. PMID: 34197451; PMCID: PMC8248699.
  116. Swaims-Kohlmeier A, Sheth AN, Brody J, Hardnett FP, Sharma S, Bonning EW, **Oforokun I**, Massud I, García-Lerma JG. Proinflammatory oscillations over the menstrual cycle drives bystander CD4 T cell recruitment and SHIV susceptibility from vaginal challenge. *EBioMedicine*. 2021 Jul;69:103472. doi: 10.1016/j.ebiom.2021.103472. Epub 2021 Jul 3. PMID: 34229275; PMCID: PMC8264117.
  117. D'Souza G, Bhondoekhan F, Benning L, Margolick JB, Adedimeji AA, Adimora AA, Alcaide ML, Cohen MH, Detels R, Friedman MR, Holman S, Konkle-Parker DJ, Merenstein D, **Oforokun I**, Palella F, Altekruze S, Brown TT, Tien PC. Characteristics of the MACS/WIHS Combined Cohort Study: Opportunities for Research on Aging With HIV in the Longest US Observational Study of HIV. *Am J Epidemiol*. 2021 Aug 1;190(8):1457-1475. doi: 10.1093/aje/kwab050. PMID: 33675224; PMCID: PMC8484936.
  118. Ahonkhai AA, Musa AZ, Fenton AA, Aliyu MH, **Oforokun I**, Hornstein A, Musa BM, Nwosu N, Ulasi I, Ajayi S, Falade C, Dada A, Abdu A, Sunday M, Odewabi A, Rotimi MK, Ogueh O, Steinbach A, Ogedegbe G, Salako BL, Ezechi OC. The CircumVent Project: a CPAP/O<sub>2</sub> helmet solution for non-invasive ventilation using an implementation research framework. *Implement Sci Commun*. 2021 Aug 26;2(1):93. doi: 10.1186/s43058-021-00193-y. PMID: 34446110; PMCID: PMC8390034.

119. Rubtsova AA, Wingood G, **Ofotokun I**, Mehta CC, Gustafson D, Vance DE, Sharma A, Adimora AA, Holstad M. Psychosocial Mechanisms of Self-rated Successful Aging with HIV: A Structural Equation Model. *AIDS Behav.* 2021 Sep;25(9):2875-2885. doi: 10.1007/s10461-021-03340-7. Epub 2021 Jun 11. PMID: 34115265.
120. Lakshmanappa YS, Roh JW, Rane NN, Dinasarapu AR, Tran DD, Velu V, Sheth AN, **Ofotokun I**, Amara RR, Kelley CF, Waetjen E, Iyer SS. Circulating integrin  $\alpha_4 \beta_7^+$  CD4 T cells are enriched for proliferative transcriptional programs in HIV infection. *FEBS Lett.* 2021 Sep;595(17):2257-2270. doi: 10.1002/1873-3468.14163. Epub 2021 Jul 26. PMID: 34278574.
121. Sheira LA, Frongillo EA, Hahn J, Palar K, Riley ED, Wilson TE, Adedimeji A, Merenstein D, Cohen M, Wentz EL, Adimora AA, **Ofotokun I**, Metsch L, Turan JM, Tien PC, Weiser SD. Relationship between food insecurity and smoking status among women living with and at risk for HIV in the USA: a cohort study. *BMJ Open.* 2021 Sep 6;11(9):e054903. doi: 10.1136/bmjopen-2021-054903. PMID: 34489299; PMCID: PMC8422493.
122. Galaviz KI, Colasanti JA, Kalokhe AS, Ali MK, **Ofotokun I**, Fernandez A. Factors associated with adherence to guideline-recommended cardiovascular disease prevention among HIV clinicians. *Transl Behav Med.* 2021 Sep 16;ibab125. doi: 10.1093/tbm/ibab125. Epub ahead of print. PMID: 34529051.
123. Breger TL, Westreich D, Edmonds A, Edwards JK, Zalla LC, Cole SR, Ramirez C, **Ofotokun I**, Kassaye SG, Brown TT, Konkle-Parker D, Jones DL, D'souza G, Cohen M, Tien PC, Taylor TN, Anastos K, Adimora AA. A new smoking cessation "cascade" among women with or at risk for HIV infection. *AIDS.* 2021 Sep 29. doi: 10.1097/QAD.0000000000003089. Epub ahead of print. PMID: 34586086.
124. Massad LS, Xie X, Minkoff HL, Michel KG, D'Souza G, Wang CC, Konkle-Parker D, **Ofotokun I**, Fischl MA, Rahangdale L, Strickler HD. Frequency of high-grade squamous cervical lesions among women over age 65 years living with HIV. *Am J Obstet Gynecol.* 2021 Oct;225(4):411.e1-411.e7. doi: 10.1016/j.ajog.2021.04.253. Epub 2021 May 3. PMID: 33957115; PMCID: PMC8492479.
125. Collins LF, Sheth AN, Mehta CC, Naggie S, Golub ET, Anastos K, French AL, Kassaye S, Taylor TN, Fischl MA, Adimora AA, Kempf MC, Palella FJ, Tien PC, **Ofotokun I**. Incident Non-AIDS Comorbidity Burden Among Women With or at Risk for Human Immunodeficiency Virus in the United States. *Clin Infect Dis.* 2021 Oct 5;73(7):e2059-e2069. doi: 10.1093/cid/ciaa1928. PMID: 33388773; PMCID: PMC8492222.
126. Cedarbaum ER, Ma Y, Adimora AA, Bamman M, Cohen MH, Fischl MA, Gustafson D, Matsushita K, **Ofotokun I**, Plankey M, Seaberg EC, Sharma A, Tien PC. Peripheral artery disease and physical function in women with and without HIV. *AIDS.* 2021 Oct 21. doi: 10.1097/QAD.0000000000003113. Epub ahead of print. PMID: 34678842.
127. Budhwani H, Yigit I, **Ofotokun I**, Konkle-Parker DJ, Cohen MH, Wingood GM, Metsch LR, Adimora AA, Taylor TN, Wilson TE, Weiser SD, Kempf MC, Sosanya O, Gange S, Kassaye S, Turan B, Turan JM. Examining the Relationships Between Experienced and Anticipated Stigma in Health Care Settings, Patient-Provider Race Concordance, and Trust in Providers Among Women Living with HIV. *AIDS Patient Care STDS.* 2021 Nov;35(11):441-448. doi: 10.1089/apc.2021.0096. PMID: 34739336.
128. Castillo-Mancilla JR, Edwards JA, Brijkumar J, Moosa MY, Zhao Y, **Ofotokun I**, Johnson BA, Lee MH, Pillay S, Pillay M, Moodley P, Kuritzkes DR, Sunpath H, Bushman LR, Ellison L, Anderson PL, Marconi VC. Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study. *J Int AIDS Soc.* 2021 Dec;24(12):e25849. doi: 10.1002/jia2.25849. PMID: 34910844; PMCID: PMC8673924.

129. Caro-Vegas C, Ramirez C, Landis J, Adimora AA, Strickler H, French AL, **Ofotokun I**, Fischl M, Seaberg EC, Wang CJ, Spence AB, Dittmer DP. Molecular profiling of breast and lung cancer in women with HIV reveals high tumor mutational burden. *AIDS*. 2021 Dec 6. doi: 10.1097/QAD.0000000000003144. Epub ahead of print. PMID: 34873086.
130. Sheth AN, Adimora AA, Golub ET, Kassaye SG, Rana A, Westreich D, Cyriaque JW, Parish C, Konkle-Parker D, Jones DL, Kempf MC, **Ofotokun I**, Kanthula RM, Donohue J, Raccamarich P, Tisdale T, Ramirez C, Warren-Jeanpierre L, Tien PC, Alcaide ML. Study of Treatment and Reproductive Outcomes Among Reproductive-Age Women With HIV Infection in the Southern United States: Protocol for a Longitudinal Cohort Study. *JMIR Res Protoc*. 2021 Dec 20;10(12):e30398. doi: 10.2196/30398. PMID: 34932006.
131. Weitzmann MN, Weiss D, Vikulina T, Roser-Page S, Yu K, McGee-Lawrence ME, Tu CL, Chang W, **Ofotokun I**. Immune Reconstitution Bone Loss Exacerbates Bone Degeneration Due to Natural Aging in a Mouse Model. *J Infect Dis*. 2021 Dec 28;jjab631. doi: 10.1093/infdis/jiab631. Epub ahead of print. PMID: 34962571.
132. Terry C, Mehta CC, Holloway J, Sheth AN, **Ofotokun I**, Abraham A, Kunisaki KM, Witt M, McCormack MC, Morris A, Drummond MB, Jensen R, Stosor V, Macatangay BJC, Cribbs SK. Dyspnea and Pulmonary Function Among Participants in the Multicenter AIDS Cohort Study Using Protease Inhibitors: A Cross-Sectional Study. *AIDS Res Hum Retroviruses*. 2021 Dec 30. doi: 10.1089/AID.2021.0082. Epub ahead of print. PMID: 34969258.
133. Breger TL, Westreich D, Edmonds A, Edwards JK, Zalla LC, Cole SR, Ramirez C, **Ofotokun I**, Kassaye SG, Brown TT, Konkle-Parker D, Jones DL, D'Souza G, Cohen MH, Tien PC, Taylor TN, Anastos K, Adimora AA. A new smoking cessation 'cascade' among women with or at risk for HIV infection. *AIDS*. 2022 Jan 1;36(1):107-116. doi: 10.1097/QAD.0000000000003089. PMID: 34586086.
134. Chen J, Titanji K, Sheth AN, Gandhi R, McMahan D, **Ofotokun I**, Weitzmann MN, De Paris K, Dumond JB. The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study. *Immun Ageing*. 2022 Jan 3;19(1):4. doi: 10.1186/s12979-021-00260-x. PMID: 34980186; PMCID: PMC8722153.
135. Kuniholm MH, Vásquez E, Appleton AA, Kingsley L, Palella FJ, Budoff M, Michos ED, Fox E, Jones D, Adimora AA, **Ofotokun I**, D'souza G, Weber KM, Tien PC, Plankey M, Sharma A, Gustafson DR. Cardiovascular risk score associations with frailty in men and women with or at risk for HIV. *AIDS*. 2022 Feb 1;36(2):237-347. doi: 10.1097/QAD.0000000000003107. PMID: 34934019; PMCID: PMC8711611.
136. Sellers SA, Edmonds A, Ramirez C, Cribbs SK, Ofotokun I, Huang L, Morris A, McCormack MC, Kunisaki KM, D'souza G, Rivera MP, Drummond MB, Adimora AA. Optimal lung cancer screening criteria among persons living with HIV. *J Acquir Immune Defic Syndr*. 2022 Feb 3. doi: 10.1097/QAI.0000000000002930. Epub ahead of print. PMID: 35125470.
137. Khalil L, Leary M, Rouphael N, Ofotokun I, Rebolledo PA, Wiley Z. Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. *Vaccines (Basel)*. 2022 Feb 14;10(2):290. doi: 10.3390/vaccines10020290. PMID: 35214748; PMCID: PMC8875029.
138. Rubin LH, O'Halloran JA, Williams DW, Li Y, Fitzgerald KC, Dastgheyb R, Damron AL, Maki PM, Spence AB, Sharma A, Gustafson DR, Milam J, Weber KM, Adimora AA, Ofotokun I, Fischl MA, Konkle-Parker D, Xu Y. Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV. *J Neuroimmune Pharmacol*. 2022 Feb 17. doi: 10.1007/s11481-021-10042-3. Epub ahead of print. PMID: 35178611.
139. Cedarbaum ER, Ma Y, Adimora AA, Bamman M, Cohen MH, Fischl MA, Gustafson D, Matsushita K, Ofotokun I, Plankey M, Seaberg EC, Sharma A, Tien PC. Peripheral artery disease

- and physical function in women with and without HIV. *AIDS*. 2022 Mar 1;36(3):347-354. doi: 10.1097/QAD.0000000000003113. PMID: 34678842; PMCID: PMC8795474.
140. Psomas CK, Hoover DR, Shi Q, Brown TT, Vance DE, Holman S, Plankey MW, Tien PC, Weber KM, Floris-Moore M, Bolivar HH, Golub ET, McDonnell Holstad M, Radtke KK, Tamraz B, Erlandson KM, Rubin LH, Sharma A. POLYPHARMACY IS ASSOCIATED WITH FALLS IN WOMEN WITH AND WITHOUT HIV. *J Acquir Immune Defic Syndr*. 2022 Mar 25. doi: 10.1097/QAI.0000000000002955. Epub ahead of print. PMID: 35333216.
  141. Price J, Ma Y, Adimora A, Fischl M, French AL, Golub ET, Konkle-Parker D, Kuniholm MH, Ofotokun I, Plankey M, Sharma A, Tien PC. Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV. *BMJ Open*. 2022 Apr 7;12(4):e055706. doi: 10.1136/bmjopen-2021-055706. PMID: 35393310; PMCID: PMC8991036.
  142. Bhavani SV, Wiley Z, Verhoef PA, Coopersmith CM, Ofotokun I. Racial Differences in Detection of Fever Using Temporal vs Oral Temperature Measurements in Hospitalized Patients. *Jama*. Sep 6 2022;328(9):885-886. doi:10.1001/jama.2022.12290
  143. Breger TL, Westreich D, Edmonds A, et al. A new smoking cessation 'cascade' among women with or at risk for HIV infection. *Aids*. Jan 1 2022;36(1):107-116. doi:10.1097/qad.0000000000003089
  144. Caro-Vegas C, Ramirez C, Landis J, et al. Molecular profiling of breast and lung cancer in women with HIV reveals high tumor mutational burden. *Aids*. Mar 15 2022;36(4):567-571. doi:10.1097/qad.0000000000003144
  145. Cedarbaum ER, Ma Y, Adimora AA, et al. Peripheral artery disease and physical function in women with and without HIV. *Aids*. Mar 1 2022;36(3):347-354. doi:10.1097/qad.0000000000003113
  146. Chen J, Titanji K, Sheth AN, et al. The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study. *Immun Ageing*. Jan 3 2022;19(1):4. doi:10.1186/s12979-021-00260-x
  147. Collins LF, Christina Mehta C, Palella FJ, et al. THE EFFECT OF MENOPAUSAL STATUS, AGE, AND HIV ON NON-AIDS COMORBIDITY BURDEN AMONG U.S. WOMEN. *Clin Infect Dis*. Jun 10 2022;doi:10.1093/cid/ciac465
  148. Galaviz KI, Colasanti JA, Kalokhe AS, Ali MK, Ofotokun I, Fernandez A. Factors associated with adherence to guideline-recommended cardiovascular disease prevention among HIV clinicians. *Transl Behav Med*. Jan 18 2022;12(1)doi:10.1093/tbm/ibab125
  149. Gardner AR, Ma Y, Bacchetti P, et al. Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment. *J Infect Dis*. Aug 11 2022;doi:10.1093/infdis/jiac315
  150. Harding JL, Oviedo SA, Ali MK, et al. The bidirectional association between diabetes and long-COVID-19 - A systematic review. *Diabetes Res Clin Pract*. Dec 7 2022;195:110202. doi:10.1016/j.diabres.2022.110202
  151. Khalil L, Leary M, Roupheal N, Ofotokun I, Rebolledo PA, Wiley Z. Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. *Vaccines (Basel)*. Feb 14 2022;10(2)doi:10.3390/vaccines10020290
  152. Kuniholm MH, Vásquez E, Appleton AA, et al. Cardiovascular risk score associations with frailty in men and women with or at risk for HIV. *Aids*. Feb 1 2022;36(2):237-347. doi:10.1097/qad.0000000000003107



153. Mehta CC, Hagen KS, Collins LF, Moore RH, Ofotokun I. Nested and multipart prospective observational studies, flaming fiasco or efficiently economical?: The Brain, Bone, Heart case study. *BMC Med Res Methodol.* Jul 25 2022;22(1):203. doi:10.1186/s12874-022-01675-w
154. Mehta CC, Hagen KS, Rubtsova AA, et al. Bone, Brain, Heart study protocol: A resilient nested, tripartite prospective cohort study of the role of estrogen depletion on HIV pathology. *PLoS One.* 2022;17(8):e0272608. doi:10.1371/journal.pone.0272608
155. Moran CA, Collins LF, Beydoun N, et al. Cardiovascular Implications of Immune Disorders in Women. *Circ Res.* Feb 18 2022;130(4):593-610. doi:10.1161/circresaha.121.319877
156. Moran CA, Oliver NT, Szabo B, et al. The association between comorbidities and coronavirus disease 2019 hospitalization among people with HIV differs by age. *Aids.* Jan 1 2023;37(1):71-81. doi:10.1097/qad.0000000000003386
157. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *Jama.* Oct 25 2022;328(16):1595-1603. doi:10.1001/jama.2022.18590
158. Peters BA, Hanna DB, Sharma A, et al. Menopausal hormone therapy and subclinical cardiovascular disease in women with and without HIV. *Clin Infect Dis.* Jul 29 2022;doi:10.1093/cid/ciac620
159. Peters BA, Xue X, Sheira LA, et al. Menopause Is Associated With Immune Activation in Women With HIV. *J Infect Dis.* Jan 18 2022;225(2):295-305. doi:10.1093/infdis/jiab341
160. Price J, Ma Y, Adimora A, et al. Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV. *BMJ Open.* Apr 7 2022;12(4):e055706. doi:10.1136/bmjopen-2021-055706
161. Price JC, Ma Y, Kuniholm MH, et al. Human Immunodeficiency Virus Is Associated With Elevated FibroScan-Aspartate Aminotransferase (FAST) Score. *Clin Infect Dis.* Dec 19 2022;75(12):2119-2127. doi:10.1093/cid/ciac337
162. Rubin LH, O'Halloran JA, Williams DW, et al. Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV. *J Neuroimmune Pharmacol.* Feb 17 2022;doi:10.1007/s11481-021-10042-3
163. Sellers SA, Edmonds A, Ramirez C, et al. Optimal Lung Cancer Screening Criteria Among Persons Living With HIV. *J Acquir Immune Defic Syndr.* Jun 1 2022;90(2):184-192. doi:10.1097/qai.0000000000002930
164. Terry C, Mehta C, Holloway J, et al. Dyspnea and Pulmonary Function Among Participants in the Multicenter AIDS Cohort Study Using Protease Inhibitors: A Cross-Sectional Study. *AIDS Res Hum Retroviruses.* Feb 2022;38(2):143-151. doi:10.1089/aid.2021.0082
165. Thompson EC, Muhammad JN, Adimora AA, et al. Internalized HIV-Related Stigma and Neurocognitive Functioning Among Women Living with HIV. *AIDS Patient Care STDS.* Sep 2022;36(9):336-342. doi:10.1089/apc.2022.0041
166. Turan B, Budhwani H, Yigit I, et al. Resilience and Optimism as Moderators of the Negative Effects of Stigma on Women Living with HIV. *AIDS Patient Care STDS.* Dec 2022;36(12):474-482. doi:10.1089/apc.2022.0185
167. Vallejo J, Saigusa R, Gulati R, et al. Combined protein and transcript single-cell RNA sequencing in human peripheral blood mononuclear cells. *BMC Biol.* Sep 1 2022;20(1):193. doi:10.1186/s12915-022-01382-4
168. Vallejo J, Saigusa R, Gulati R, et al. Author Correction: Combined protein and transcript single-cell RNA sequencing in human peripheral blood mononuclear cells. *BMC Biol.* Oct 20 2022;20(1):237. doi:10.1186/s12915-022-01440-x

169. Weitzmann MN, Weiss D, Vikulina T, et al. Immune Reconstitution Bone Loss Exacerbates Bone Degeneration Due to Natural Aging in a Mouse Model. *J Infect Dis.* Aug 12 2022;226(1):38-48. doi:10.1093/infdis/jiab631
170. Williams DW, Flores BR, Xu Y, et al. T-cell activation state differentially contributes to neuropsychiatric complications in women with HIV. *Brain Behav Immun Health.* Nov 2022;25:100498. doi:10.1016/j.bbih.2022.100498
171. Young MR, Wall KM, Dude CM, et al. *Trichomonas vaginalis* and Spontaneous Preterm Birth in a High-Risk Obstetric Cohort in Atlanta, GA. *Sex Transm Dis.* Sep 1 2022;49(9):644-648. doi:10.1097/olq.0000000000001654
172. Moran CA, Oliver NT, Szabo B, Collins LF, Nguyen MLT, Shah NS, Moanna A, Colasanti JA, Cantos VD, Armstrong WS, Sheth AN, Ofotokun I, Kelley CF, Marconi VC, Lahiri CD. The association between comorbidities and coronavirus disease 2019 hospitalization among people with HIV differs by age. *AIDS.* 2023 Jan 1;37(1):71-81. doi: 10.1097/QAD.0000000000003386. Epub 2022 Sep 15. PMID:36111530; PMCID: PMC9742289.
173. Shitole SG, Lazar JM, Taub CC, Furlani AC, Konkle-Parker DJ, Dionne-Odom J, Fischl MA, Ofotokun I, Adimora AA, Topper EF, Golzar Y, Kassaye SG, Gustafson D, Anastos K, Hanna DB, Xue X, Tien PC, Kaplan RC, Kizer JR. Human Immunodeficiency Virus and Cardiac End-Organ Damage in Women: Findings From an Echocardiographic Study Across the United States. *Clin Infect Dis.* 2023 Jan 13;76(2):210-219. doi:10.1093/cid/ciac795. PMID: 36184972.
174. McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, Jayaweera D, Sulkowski M, Gentile N, Bramante C, Singh U, Dolor RJ, Ruiz-Unger J, Wilson S, DeLong A, Remaly A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Thicklin F, Hanna G, Ginde AA, Castro M, McTigue K, Shenkman E, Hernandez AF; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *JAMA.* 2023 Jan 12. doi: 10.1001/jama.2022.24100. Epub ahead of print. PMID: 36633838.

**b. Manuscripts Submitted:**

**c. Published abstracts**

1. Swaims A\*, Haaland R; Evans-Strickfaden T, Haadad L, Sheth A, Lupo L, Cordes S, Aguirre A, Lupoli K, Chen CY, **Ofotokun I**, Kohlmeier J, Hart C. Recirculating HIV-target T lymphocytes at the mucosal surface of the female genital tract are associated with progesterone increases during the menstrual cycle. Conference: Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY) Location: New Orleans, LA Date: MAY 08-12, 2015, Sponsor(s): Amer Assoc Immunologists JOURNAL OF IMMUNOLOGY Volume: 194 Supplement: 1 Meeting Abstract: MUC2P.938 Published: MAY 1, 2015
2. Sheth AN\*, Swaims-Kohlmeier A, Haaland RE, Lahiri CD, Carlson RD, Aguirre AJ, Evans-Strickfaden T, Brown NL, Lupo LD, Mehta CB, Hart CE, **Ofotokun I**. Oral Maraviroc Reduces CD4 T Cells at the Genital Mucosal Surface of HIV-seronegative Women: Conference on HIV Research for Prevention (HIV R4P) Location: Chicago, IL Date: OCT 17-20, 2016, AIDS RESEARCH AND HUMAN RETROVIRUSES Volume: 32 Supplement: 1 Pages: 305-305 Meeting Abstract: P18.02 Published: OCT 2016
3. Kohlmeier A\*, Haddad L, Haaland R, Lupo D, **Ofotokun I**, Hart C, Kohlmeier JE. Distinct migratory phenotypes of luminal CD4 T cell subsets in the female genital tract. Conference: Annual Meeting of the American-Association-of-Immunologists (AAI) Location: Seattle, WA Date: MAY 13-17, 2016 Sponsor(s): Amer Assoc Immunologists JOURNAL OF IMMUNOLOGY Volume: 196 Supplement: 1 Published: MAY 1 2016

4. Topel ML\*, Hayek SH, Wadhvani S, Moran C, Staloch DA, Wei CL (Wei, Reiser J, **Ofotokun I**, Quyyumi AA. HIV-positive Individuals with Undetectable Viral Loads Have suPAR Levels Comparable to HIV-negative Individuals. Scientific Sessions of the American-Heart-Association on Epidemiology and Prevention/Lifestyle and Cardiometabolic Health. Sponsor(s): Amer Heart Assoc CIRCULATION Volume: 135 Supplement: 1 Meeting Abstract: P261 Published: MAR 7 2017

**d. Review Articles:**

1. Markovitz DM, Gitlin SD, **Ofotokun I**. Reply to: Thrombosis, vasculitis, and cytomegalovirus infection. *Clin Infect Dis* 2002;34:1659-60.
2. **Ofotokun I**, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. *Top HIV Med.* 2003 Mar-Apr;11(2):55-9. PMID: 12717043.
3. **Ofotokun I**. Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. *Top HIV Med.* 2005 Jun-Jul;13(2):79-83. PMID: 16082059.
4. **Ofotokun I**, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. *Gend Med.* 2007 Jun;4(2):106-19. doi: 10.1016/s1550-8579(07)80025-8. PMID: 17707845.
5. **Ofotokun I**, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. *Curr Opin Endocrinol Diabetes Obes.* 2010 Dec;17(6):523-9. doi: 10.1097/MED.0b013e32833f48d6. PMID: 20844427; PMCID: PMC3632052.
6. **Ofotokun I**, Weitzmann MN. HIV and bone metabolism. *Discov Med.* 2011 May;11(60):385-93. PMID: 21616037; PMCID: PMC3593269.
7. **Ofotokun I**, McIntosh E, Weitzmann MN. HIV: inflammation and bone. *Curr HIV/AIDS Rep.* 2012 Mar;9(1):16-25. doi: 10.1007/s11904-011-0099-z. PMID: 22179898; PMCID: PMC3286635.
8. James AM, **Ofotokun I**, Sheth AN, Acosta EP, King KR. Tenofovir: Once-daily Dosage in the Management of HIV Infection. *Clinical Medicine Insights: Therapeutics* 2012;4 201-216
9. Remick J, Georgiopoulou V, Marti C, **Ofotokun I**, Kalogeropoulos A, Lewis W, Butler J. Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research. *Circulation.* 2014 Apr 29;129(17):1781-9. doi: 10.1161/CIRCULATIONAHA.113.004574. PMID: 24778120; PMCID: PMC4006343.
10. Ali MK, Magee MJ, Dave JA, **Ofotokun I**, Tungsiripat M, Jones TK, Levitt NS, Rimland D, Armstrong WS. HIV and metabolic, body, and bone disorders: what we know from low- and middle-income countries. *J Acquir Immune Defic Syndr.* 2014 Sep 1;67 Suppl 1:S27-39. doi: 10.1097/QAI.0000000000000256. PMID: 25117959.
11. Larson KB, Wang K, Delille C, **Ofotokun I**, and Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. *Clin Pharmacokinet.* 2014 Oct;53(10):865-72. PMID:25164142
12. Haddad LB, Polis CB, Sheth AN, Brown J, Kourtis AP, King C, Chakraborty R, **Ofotokun I**. Contraceptive Methods and Risk of HIV Acquisition or Female-to-Male Transmission. *Curr HIV/AIDS Rep.* 2014 Oct 9. PMID:25297973
13. Moran CA, Weitzmann MN, **Ofotokun I**. The protease inhibitors and HIV-associated bone loss. *Curr Opin HIV AIDS.* 2016 May;11(3):333-42. doi: 10.1097/COH.0000000000000260. PMID: 26918650; PMCID: PMC4838480.
14. Weitzmann MN, **Ofotokun I**. Physiological and pathophysiological bone turnover - role of the immune system. *Nat Rev Endocrinol.* 2016 Sep;12(9):518-32. doi: 10.1038/nrendo.2016.91. Epub 2016 Jun 17. PMID: 27312863; PMCID: PMC5857945.

15. Weitzmann MN, **Ofotokun I**, Titanji K, Sharma A, Yin MT. Bone Loss Among Women Living With HIV. *Curr HIV/AIDS Rep.* 2016 Dec;13(6):367-373. doi: 10.1007/s11904-016-0336-6. PMID: 27678124; PMCID: PMC5120862.
16. Moran CA, Weitzmann MN, **Ofotokun I**. Bone Loss in HIV Infection. *Curr Treat Options Infect Dis.* 2017 Mar;9(1):52-67. doi: 10.1007/s40506-017-0109-9. Epub 2017 Feb 23. PMID: 28413362; PMCID: PMC5388454.
17. Hussen SA, Kuppalli K, Castillo-Mancilla J, Bedimo R, Fadul N, **Ofotokun I**. Cultural Competence and Humility in Infectious Diseases Clinical Practice and Research. *J Infect Dis.* 2020 Sep 14;222(Suppl 6):S535-S542. doi: 10.1093/infdis/jiaa227. PMID: 32926742; PMCID: PMC7489471.
18. Scherer EM, Backer M, Carvajal K, et al. The COVID-19 Pandemic Unmasked the Challenges Faced by Early-Stage Faculty in Infectious Diseases: A Call to Action. *Clin Infect Dis.* Sep 22 2022;doi:10.1093/cid/ciac779
19. Wiley Z, Khalil L, Lewis K, et al. A Framework for Inspiring COVID-19 Vaccine Confidence in African American and Latino Communities. *Vaccines (Basel).* Aug 15 2022;10(8)doi:10.3390/vaccines10081319

#### d. Editorials

1. **Ofotokun I**. Deciphering how HIV-1 weakens and cracks the bone. *Proc Natl Acad Sci U S A.* 2018 Mar 13;115(11):2551-2553. doi: 10.1073/pnas.1801555115. Epub 2018 Mar 1. PMID: 29496959; PMCID: PMC5856569.
2. Frew PM, Lutz CS, **Ofotokun I**, Marconi VC, Del Rio C. Geospatial mapping to identify feasible HIV prevention and treatment strategies that target specific settings. *Ann Transl Med.* 2018 Feb;6(3):59. doi: 10.21037/atm.2017.12.20. PMID: 29610750; PMCID: PMC5879532.
3. **Ofotokun I**, Sheth AN. Africa's COVID-19 Experience-A Window of Opportunity to Act. *JAMA Netw Open.* 2021 Sep 1;4(9):e2124556. doi: 10.1001/jamanetworkopen.2021.24556. PMID: 34519772.

#### e. Book Chapters:

1. **Ofotokun I**. The emerging acquired immunodeficiency syndrome (AIDS) catastrophe in Nigeria. The hope factor: Engaging the Church in the HIV/AIDS crisis. Edited by T. Yamamori, D. Dageforde, T. Bruner Published by Authentic Media, 2003.
2. Haddad L, Tarleton J, Sheth AN, **Ofotokun I**. "Contraception for women living with HIV." *Contraception for the Medically Challenging Patient.* New York, NY: Springer, 2014.
3. Sheth AN, Delille C, **Ofotokun I**. Sex Differences in Metabolism and Pharmacokinetics. New York, NY: Springer, 2014.
4. Lahiri DC, Lennox JL, **Ofotokun I**. Protease Inhibitors. New York, NY: Springer, 2016.

#### f. Manuals, Videos, Computer Programs, and Other Teaching Aids:

1. **Ofotokun I**, University of Kentucky Medical Center 2002-2003 Empiric Antimicrobial Therapy Manual.